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ABSTRACT 
Age-related cataract is the commonest cause of treatable blindness in the 
world today. It is an ever-increasing probleth with prolonged life-expectancy and a 
burgeoning elderly population. Although successfully treated by modem, 
sophisticated cataract surgery, the resources needed to provide a surgical set-up and 
the prolonged training time required to produce a competent surgeon can challenge 
the available finances of developed economies and result in unacceptable waiting 
times while they may simply be unaffordable in developing economies and result in 
high prevalence of blindness. Surgical treatment, although effective in dramatically 
reversing blindness, is associated with a small risk of sight-threatening complications. 
Against this background, it is worth considering an alternative, simpler, medical 
means of treating cataracts that is easily administered and equally effective. 
Calpains are Ca2tdependent 
 intracellular proteases and several of these 
enzymes are believed to participate in cataractogenesis. Calpain 2 is the major isoform 
of calpain involved in human cataractogenesis and its activation appears to be 
investigate the mechanism of lipid activation of calpains as an essential link towards 
understanding the molecular and cellular dynamics of cataractogenesis in vivo. A 
clear picture of the enzymatic events in cataractogenesis will form the basis of drug 
development to cause selective enzyme inhibition. 
In chapter 2, atomic absorption spectroscopy shows that the progressive 
uptake of extra-lenticular Ca 2 by porcine lenses correlates with increases in levels of 
lens opacification with 8.0 j.tmoles Ca 2 (gm wet lens weight)' corresponding to 
cataract occupying approximately 70% of the lens cell volume. This degree of cataract 
I 
was reduced by approximately 40%, when a calpain inhibitor, SJA6017 (final 
concentration 0.8 .tM), was included in the extra-lenticular medium, therefore 
suggesting that the observed porcine opacifications involve the Ca 2tmediated 
activation of calpains and that cataract could be retarded by the topical administratiOn 
of calpain inhibitors. 
In chapter 3, DWIH (Depth weighted insertion hydrophobicity) analysis shows 
the small subunit of several calpain 2 isozymes to each posess a segment with the 
potential to form a lipid / membrane interactive a-helix (DWIH values circa 7.0). 
Extended hydrophobic moment analysis shows these segments to be potential oblique 
orientated a-helix formers (cc J.1H > circa 0.5). This potential is confirmed by 
hydropathy plot and graphical analyses, which show each a-helix to possess a 
significant N -, C hydrophobicity gradient. It is suggested that the lipid / membrane 
activation of calpain 2 may involve oblique angled membrane penetration by an a-
helical segment in domain V of the enzyme. 
In chapter 4, VP1, a peptide homologue of this domain V segment, is shown to 
be strongly haemolytic (half-maximal lyric dose = 1.45 mIVI). FTIR conformational 
analysis shows VP1 to adopt a-helical structure (20% - 65% of primary structure) in 
the presence of lipids. These levels are maximal in the presence of anionic lipid (65% 
of primary structure) and monolayer studies show the peptide to exhibit high levels of 
anionic lipid monolayer penetration with surface pressure changes (A SP) of 5-6 mN 
at 30 mN m, which are reduced by approximately 40% ±15% in the presence of 
100 mM NaCl. It is suggested that membrane penetration by the domain V a-helix of 
	 - 
calpain 2 may proceed via electrostatic interactions and snorkelling, involving 
associations between an arginine residue located in the polar face of this a-helix and 
anionic membrane lipid. 
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It has been suggested that lipid / membranes may modulate calpain 2 activity 
by lowering the enzyme's in vivo Ca2 requirements. In chapter 5, colorimetric assay 
of calpain 2 shows that the enzyme requires 4 mM Ca 2 for 100% proteolytic activity, 
as defined by this assay. In the presence of 1 mM Ca 2t negligible calpain 2 
proteolysis is detected but at this level of Ca 2 , in the presence of either Dimyristoyl 
phosphatidylinositol(DMPI), Dimyristoyl phosphatidylserine(DMPS), Dimyristoyl 
phosphatidylcholine(DMlPC) or Dimyristoyl phosphätidylethanolamine(DMPE), 
calpain 2 shows proteolytic activity which ranges between 37% and 77% of the 
protein's full enzymatic activity. The large subunit of calpain 2 (LS-calpain 2) is 
proteolytical]y active in the absence of the calpain 2 small subunit and it has been 
suggested that this latter subunit is dispensable for the lipid activation of calpain 2. 
LS-calpain 2 is assayed under conditions corresponding to those used here for calpain 
2 assay and is shown to require the presence of 6 mM Ca 2 for 100% enzymatic 
activity. These Ca 2 levels are unaffected by the presence of either: DMPI, DMPS, 
DMPC or DMPE, and based on these combined results, it is suggested that the lipid 
activation of calpain 2 requires the presence of the small subunit. In addition, it is 
ThhöWifthM hii ëö ãrëdtbWittëfiöiiëiij5idiiiidefcorrespondiii bUitiöñ 
anionic lipid induces an approximate twofold enhancement of calpain 2 proteolytic 
activity (70% - 77% as compared to 37% - 49%) and a similar enhancement in its 
average rates of lipid monolayer interaction (ASP = 1.5 x 10 mN M' sec 4 at 10 mN 
M' as compared to ASP = 5.0 x 10 4 mN M' sec' at 10 mN M 1 ). It is suggested that - 
calpain 2 may posess an electrostatically driven preference for anionic lipid, which 
contributes to lowering the enzyme's Ca 2 requirement for activation. 
In chapter 6, these combined data are discussed in relation to a model for the 
lipid activation of calpain 2 and proposals for future work are presented. 
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CHAPTER 1 
Cataract and calpains 
Biswas, S., Harris, F., Dennison, S., Singh, J. and Phoenix, D. A. (2003) The role of 
calpains in cataract and their potential to act as targets in cataract therapy. J. Equa. In 
press; Biswas, S., Harris, F., Dennison, S., Singh, J. and Phoenix, D. A. (2003) 
Calpains: targets of cataract prevention? Trends Mol. Med. In press. 
1.1 INTRODUCTION 
The ocular lens is a highly specialised non-vascular tissue, which focuses an 
image onto the retina of the eye, triggering electrical impulses that will then be 
interpreted by the brain as vision. (Figure 1.1; Harding et cii., 1997). In cataract, 
opacification of all or part of the lens prevents visible light from reaching the retina, 
reducing optical performance and is most commonly manifested by decreased visual 
acuity, glare and contrast sensitivity (Truscott, 2003; Johnson et at, 1998). 
Cataract accounts for the majority of cases of treatable blindness world-wide 
and is a major detriment to the quality of life. The disorder can be caused by a variety 
of factors including: ageing (Harding, 2002) metabolic disturbances, radiation, 
trauma, drugs (Brown and Bron, 1996a) and congenital disorders (Francis et cii., 
1999). Aetiologically, the most common types of cataract are those associated with 
ageing (Harding, 2002), followed by those associated with diabetes (Bron et al., 
1998). Age-related cataract involves both changes in the lens cortex, giving rise to 
cortical cataract, and in the lens nucleus, leading to nuclear cataract (Bron et al., 
2000). Below the age of 50, women have a lower incidence of cataract than men, but 
above that age the incidence is greater. A hormonal influence in cataractogenesis has 
been suggested and indeed, women undergoing hormone replacement therapy have a 
significantly reduced incidence of cortical cataract when compared to men (Brown 
and Bron, 1996b). In human diabetic cataracts, opacities are observed in various 
regions of the lens, and the posterior, subcapsular or cortical types are common in the 
early stage. In the cortical type of diabetic cataract, opacities spread along lens fibres 
from the equator to the centre and the cortex appears to be the lens region 
predominantly involved in human cataract under long-term diabetic stress (Bron et cii., 
1998). 
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Figure 1.1 A schematic cross-section of the human eye 
Figure 1.1 was adapted from Biswas et al., (2004) and shows the location of the lens 
in the human eye. The ocular lens is a highly specialised non-vascular tissue, which 
focuses an image onto the retina of the eye, triggering electrical impulses that will 
then be interpreted by the brain as vision. In cataract; opacification of all, or part, of 
the lens prevents visible light from reaching the retina, which reduces optical 
performance and is most commonly manifested by decreased visual acuity, glare and 
contrast sensitivity (Bron, 2000). Also shown in Figure 1.1 is a magnified image of 
the-lensdepicting_itsmajor_anatocalregions_each_of_whjth flits own or in 
combination can undergo opacification to form localised cataract or a total 'mature' 
cataract. Cataracts caused by steroid treatment are localised to the posterior sub-
capsular region of the lens. Age-related cataract, which is the most common group of 
cataracts worldwide, can start either in the cortex, or in the nucleus, although it 
eventually affects both regions and this is also true of cataracts in diabetic people. The 
anterior epithelial layers and cortical regions of human cataract have been shown to 
contain calpain 2, a key enzyme implicated in the genesis of some forms of cataract 
(Sanderson et at, 2000). 
In many cases the precise underlying mechanisms that lead to cataract are not 
fully understood (Biswas et al., 2003). The lens changes involved in cataractogenesis 
may be considered to be either specific or general in nature. Specific lens changes are 
related to the aetiology of the cataract, a major example of which is seen with 
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diabetics where the effects of sugar-mediated changes to the lens are perhaps, not 
surprisingly, much higher than in age-matched non-diabetics (Bron et al., 1998). 
General changes associated with the normal ageing of the lens are also observed in 
cataract although such changes are generally greater in the case of cataract (Harding, 
2002; Bron et al., 2000). These lens changes include: alterations to membrane lipid 
structure, thereby compromising membrane functions (Tang et al., 2003a; Zheng et 
al., 1999; Ahuja et al., 1999) changes in the levels of lens enzyme activity, 
particularly in anti-oxidant enzyme systems (Lou, 2003; Lou, 2000) and the structural 
modification of a variety of membrane associated proteins (Sanderson et al., 2000; 
Clark et al., 1999; Matsushima et al., 1997; Andersson et al., 1996). However, in most 
cases of cataract, the major change associated with reduced optical performance of the 
lens is the structural modification of the water-soluble crystallins (Figure 1.2). 
Crystallins are primarily responsible for lens transparency and their structural 
modification usually leads to compromised function, aggregation and insolubilisation 
with elevated levels of these processes resulting in cataract (Dubbelman et al., 2003; 
Fujii, 2003; Derham and Harding, 2002; Fujii et al., 2001). A number of lens insults 
iF&khb'K kiindjjaei&SIsjallijj difiëãtimiaWdleiiiToifieIioij7FfjjkeThtTht; 
2003; Stitt, 2001; Spector, 2000; Ottonello et al., 2000) but over the last decade it has 
become increasingly clear that members of the calpain family of proteases may 
participate in these processes in response to the elevation of internal Ca 2 levels that 
are observed in cataractogenesis (Figure 1.2; Biswas et al., 2003; Biswas et al., 2001).. 
Here, recent research into the roles played by calpain 2, calpain 10 and lens specific 
isoforms of calpain 3 in cataractogenesis is reviewed with a focus on crystallin 
proteolysis, the activation of these calpains in the lens and the potential use of calpain 
inhibitors as anti-cataract agents. 
Figure 1.2 Representative lens pathways leading to calpain activation 
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Figure 1.2 was adapted from Biswas et al., (2004) and shows biochemical pathways 
that can induce light scattering and cataract. The ageing process and lens insults such 
as oxidation and diabetes, can lead to impaired membrane function, which results in 
pathologically elevated levels of lenticular Ca 2 (Lou, 2003; Stitt, 2001). Under these 
Ca2 conditions, cálpains are over-activated and the resulting deregulated proteolysis 
of soluble crystallins leads to their insolubilisation and aggregation, thereby 
compromising their function(s) in maintaining lens transparency and producing the 
reduced lens performance associated with cataract. Over-activated calpains also 
proteolyse lens cytoskeletal proteins such as vimentin, which, can further elevate 
, 	
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(Biswas et al., 2001; Sanderson et aL, 2000). Calpains have been implicated in a 
number of cellular processes (Ray et al., 2003; Nixon, 2003; Huang and Wang, 2001) 
but for clarity, these biochemical pathways are not shown. 
1.2 CRYSTALLIN FUNCTION IN THE LENS 
Essentially, the bulk of the lens is formed from densely packed elongated fibre 
cells, which are arranged in concentric shells (Harding, 1997) with a single-celled 
surface layer of epithelial cells (13hat, 2001). The transparency of the lens is a function 
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of the highly ordered arrangement of the macro-molecular components of its cells and 
the extracellular matrix. The epithelial cell surface layer of the lens and its capsule 
neither scatter or reflect light, essentially because their combined refractive index is 
the same as that of the eye's aqueous humour (Paterson and Delamere, 1992). The 
regular organization of the lens fiber cells in a hexagonal, densely packed cellular 
arrangement increases the transmission properties of the lens (Francis et a]., 1999). 
Functionally, lens fibre cells are highly specialised. During development, these cells 
become devoid of nuclei and organelles to reduce light scattering, and are thus, 
metabolically inactive, being entirely dependent upon the epithelial cells (Bhat, 2001) 
and a network of gap junctions for metabolic and ionic homeostasis (White and 
Bruzzone, 2000; Vamey and Weiler, 2000). When mature, these cells become 
specialized for the production of crystallins; which are responsible for the high 
refractive index of the lens. Birefringence, as shown by the ocular lens, is an optical 
property arising from a high degree of order in a structure and it has been shown that 
at high concentrations, crystallins are capable of a high degree of packing regularity 
(Duncan et al., 1997). It is generally accepted that lens transparency is predominantly 
the result of such packing by the crystallins with the high levels of short range itial 
order produced by these packing arrangements allowing light scatter from individual 
molecules to cancel each other out (Delaye and Tardieu, 1983). 
1.3 CRYSTALLINS IN CATARACT 
Crystallins comprise three main classes: a-crystallins 0-crystallins and 'y-
crystallins (Horwitz, 2003; Jaenicke and Slingsby. 2001 Slingsby and Clout, 1999). In 
addition to their established role in maintaining transparency, it has now been shown 
that a-crystallins function as molecular chaperones by suppressing the unfolding of 
crystallins, other proteins and probably certain lens enzymes or by mediating in the 
refolding of unfolded proteins (Derham and Harding, 2002; Goenka et al., 2001; 
Horwitz, 2000). 
Functional cz-crystallins and j3-crystallins are multimeric protein complexes 
whilst y-crystallins are monomeric with each of these protein classes primarily 
possessing J3-sheet structures (Horwitz, 2003; Jaënicke and Slingsby. 2001 Slingsby 
and Clout, 1999). The crystallins can be structurally modified in response to ageing 
and a number of lens insults (Zhang et al., 2003; Lapko et al., 2003; Davies and 
Truscott, 2001; Hanson et al., 2000; Zarina et al., 2000; Liang and Ahktar, 2000; 
Hanson et al., 1998; Lampi et al., 1998). For example, the non-enzymatic glycation of 
crystallins involves the attachment of carbohydrate molecules to their amino acid 
residues, modifications which have been shown to inhibit crystalline function and to 
lead to reduced optical performance in ageing lenses and to contribute to cataract 
(Pokupec et al., 2003; Lehman and Ortwerth, 2002; Ulrich and Cerami, 2001). 
However, the major form of crystallin modification resulting from lens insult involves 
the oxidation of their thiol containing residues. To maintain clarity of the lens, it is 
generally necessary for the methionine and cysteine amino acid residues of crystallins 
to be maintained in the reduced state and their oxidation can lead to cross-linking by 
disulphide bridge formation, thereby facilitating crystallin aggregation and 
insolubilisation. These effects are prone to occur with crystallins possessing surface-
located thiol groups and contribute to the reduced optical performance normally 
observed with the general ageing process. However, when these effects are associated 
with lens insult, they generally involve higher levels of residue oxidation, increased 
unfolding of crystallins and the exposure of buried cysteine groups to oxidation. The 
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disulfide bonds thereby generated, cause high levels of crystalline aggregation and 
insolubilisation and generally cataract (Lou, 2003; Lou, 2000; Hanson, 2000; Lund et 
al., 1996). 
In addition to oxidative damage, it has become increasingly clear over the last 
ten years that pathological stmctural modifications to lens crystallins also arise from 
their proteolytic cleavage. It is now believed that Ca 2tmediated insult of the lens may 
lead to crystallin processing via the over-activation of lens proteases, thereby 
contributing to both age-related changes in the lens and some forms of cataract. 
1.4 Ca24 AND CATARACT 
Ca2 plays an essential role in many lens processes and the maintenance of 
Ca2 homeostasis is critical to lens clarity with free Ca 2 levels in the lens needing to 
be kept in the submicromolar range, lower than that of the aqueous humour (Duncan 
et aL, 2002; Duncan et al., 1994). To maintain this homeostasis, the inward passive 
et alTI986Yis  coun1eredTh9 
the use of a variety of Ca2tadenosine 
 triphosphatases (Ca2 -ATPases) and C2t1Na 
exchangers, variously located in the plasma membrane, sarcoplasmic membrane and 
endoplasmic reticular membrane (figure 1.3; Liu et al., 2002; Bian et al., 2000; 
Churchill and Louis, 1999; Liu et al., 1999; Duncan et al., 1994 Ye and Zadunasky, 
1992). 
The mechanisms that regulate Ca 2 homeostasis in lens fibre cells are not well 
understood. Deep lens fibers do not posess organelles and therefore have lost the 
means to synthesise ATP to a significant extent, although low concentrations of ATP 
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may be produced by glycolysis (Bassnett, 2002). Earlier studies have shown that there 
is no significant Ca 2 -ATPase activity in the lens nucleus (Borchman et al. 1988). 
Figure 1.3 Mechanisms involved in the regulation of lens cell internal Ca 2 
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Figure 1.3 was adapted from Duncan et al., (1994) and shows mechanisms involved in 
Ca2thomeostasis 
 in a representative lens cell. These mechanisms include passive 
influx through different channel types and efflux via at least two active transport 
mechanisms. Most Ca 2 efflux in the resting cell is performed by Ca2tATPases 
 with 
contributions from Ca 2 INa exchangers, depending upon cellular conditions. Calcium 
storage can also occur through sequestration in the cytosol and membrane, 
represented above by shaded areas, and through incorporation into dynamic 
cytoplamsic stores within the endoplasmic reticulum. 
Borchman et al. 1989). However, it has been recently suggested that gap junctions 
may play a role in the Ca 2 homeostasis of lens fibre cells (Baruch et al., 2001). Gap 
junctions are formed by hexameric structures of connexin molecules that interact with 
their counterparts in neighbouring cells to form membrane aqueous pores (Evans et 
al., 2002). These pore systems appear to mediate the transport of Ca 2 (Paemeleire et 
al., 2000) and 0 connexin is a gap junction protein expressed in lens fibre cells 
(Vaney and Weiler, 2000). Knockout mice for 0 connexin (-I-) have been generated 
(Gong et al., 1998) and when lenses from 0 (-I-) mice were recently compared to 
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those of wild type mice, an age-dependent rise in the total Ca 2 of the lens nuclear 
regions of the genetically modified mice was observed. These elevations in nuclear 
Ca2 were due to both increased Ca 2 influx and reduced Ca 2 efflux and correlated 
spatially and temporally, with nuclear cataract formation (Baruch et al., 2001). 
Recent studies have suggested that the maintenance of Ca 2 homeostasis in 
lens epithelial cells may involve gap junctions (Churchill et al., 2001) but currently, 
the primary mechanism involved in this maintenance appears to be C a2tATPase 
activity (Duncan et al., 1994). During normal ageing processes, the increased entry of 
Ca2 into the clear lenses is usually compensated for by increased activity of Ca 2t 
ATPases (Zeng et al., 1995; Duncan et al., 1993). However, age related changes that 
are detrimental to the lens can decrease the efficiency of these compensatory 
mechanisms and in cataract, their efficiency is greatly reduced - showing 
approximately 50% of their normal cellular activity (Paterson et al., 1997). Ca 2t 
ATPase are particularly sensitive to oxidation and it has been suggested that 
progressive oxidative damage to Ca2tATPases 
 leads to decreased activity of these 
proteins, resulting in the elevated Ca 2 levels associated with cataract and the reduced 
optical performance of aged lenses (Ahuja et al., 1999). Ca2tATPases 
 are also 
sensitive to membrane lipid order (Zeng et al., 1999; Delamere et al., 1991), which 
changes during cataractogenesis (Paterson et al., 1997; Borchman et al., 1993) and 
ageing (Zeng et al., 1999), and several studies have suggested that decreased Ca 2 -
ATPase activity may be related to structural changes in membrane lipid (Paterson et 
at, 1997; Borchman et al., 1993). Most recently, studies on human lenses showed that 
that lens lipids have a high capacity to bind Ca 2 and that decreases in this capacity 
lead to elevated Ca 2 levels and increased light scattering from lipids and especially 
proteins, possibly indicating a further mechanism that may lead to elevated Ca 2 
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levels in the lens (Tang et al., 2003b). Moreover, studies involving C a2tsensitive 
microelectrodes to probe localised cortical opacities, and surrounding clear regions, 
have shown that Ca2 is elevated only in the disrupted areas (Duncan, 1997). 
Elevated Ca 2 levels are known to be associated with a number of processes 
that are detrimental to the lens (Rhodes et al., 2003; Tang et al., 2003a; de Valle, 
2002; Biswas et al., 2001; Hightower and Misiak, 1998) including the overactivation 
of Ca2tdependent enzymes. Transglutaminase for example has been shown to process 
a number of enzymes associated with cataractogenesis (Shridas et al., 2001; 
Sanderson et al., 2000; Clement et al., 1998; Lorand et aL, 1998) but the major 
enzymes implicated in this eye disorder are the calpains. 
1.5 CALPAINS AND CATARACT 
Calpains are a growing superfamily of Ca 2 -dependent structurally related 
intracellular cysteine proteases (Goll et aL, 2003; Perrin and Huttenlocher, 2002; 
Sorimachi and Suzuki, 2001; Wang, 2000). Calpain 2 (Shearer et al., 2000; Azuma et 
aL, 1997), calpain 10 (Ma et at, 2001) and the calpain 3 splice variants, Lp82 (Ma et 
al., 1998a; Ma et al., 1998b) and Lp85 (Ma et al., 2000a) are the major calpains 
known to be expressed in the lens (Figure 1.4). Numerous studies have shown that 
calpain inhibitors can retard and inhibit cataractogenesis (Biswas et at, 2003; 
Nakamura et at, 2002; Quian and Shichi, 2000; Wang and Yuen, 1994) whilst recent 
studies have suggested that multiple calpains may be involved in cataractogenesis 
(Azuma et al., 2001; Takeutchi et at, 2001; Tomohiro et aL, 1997). There is 
accumulating evidence that in response to elevated levels of Ca 2t the proteolysis of 
crystallins by calpain 10, Lp82, Lp85 and calpain 2 may contribute to cataractogenesis 
(Huang and Wang, 2001; Shearer et al., 2000; Azuma et al., 1997). 
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Figure 1.4 The structural organisation of calpains expressed in the lens 
I. 	 IF 
	 m 	 •ErV 
04ig1h2 I 	 I - 
	
I 	 .1 	 U 
NIL 
. v s
Sri 
CalØa162srnal1subGhrt 
 
bièinä INs t .IIIJ_1 1S2 1 
çalpalnlo LU_-' __m_I$uqntWO 
Figure 1.4 was adapted from Biswas et al., (2004) and shows the structural 
organisation of lens calpains implicated in cataractogenesis. Calpain 2 (and calpain 1) 
is dimeric, possessing a large subunit comprising domains I-TV and a smaller subunit 
comprising domains V-VI. Calpain 10 and calpain 3 are monomeric, possessing the 
structural organisation of the calpain 2, larger subunit, except that calpain 3 possesses 
a novel N-terminus (NS) and the unique inserts, IS1 and 152, in domains II and IV 
respectively. Lp82 (and Lp85) is a lens specific variant of calpain 3, lacking 151 and 
152, and possessing a modified N-terminal region (AX1). Also represented above, in 
domain IV of calpain 2 and calpain 3 are five EF-hand motifs, which appear to be 
-- 
However, calpain 10 lacks domain IV and these EF-hands, instead possessing a 
divergent T domain (Goll et al., 2003; Ma et al., 2001; Ma et al., 2000). Annotated in 
domain H of the above calpins is the triad of amino acid residues that forms the 
active site of all calpains, C, H and N. Essentially, the thiol group of this cysteine 
residue directly participates in catalytic cleavage of the substrate peptide bond. The 
histidine residue, which is in close spatial proximity is also essential for the cysteine 
protease activity of calpains whilst other nearby residues provide groups for general 
acid-base catalysis (Reverter et a]., 2001). A three-dimensional representation of 
residues forming the active site of calpain 2 is included within Figure 1.5. 
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13.1 Calpain 10 
Polymorphisms in both calpain 10 and its parent gene, CA4PNJO, have been 
associated with human diabetes mellitus (Harris et al., 2003; Horikawa et al., 2000). 
Recently, Sakamoto-Mizutani et al., (2002) studied calpain 10 in the lenses of Wistar 
BonnlKobori (WBN/Kob) rats, which spontaneously exhibit diabetic cataract 
(Nakama et al., 1985). These lenses were fractionated and immunoblot analysis 
showed calpain 10 to be predominantly present in the water-insoluble fraction of the 
lens cortex (Sakamoto-Mizutani et al., 2002). Male WBN/Kob rats develop cortical 
cataract at 1 year of age and co-incident with the onset of this cataract, lenses from 
these rats showed large rises in intracellular Ca 2t which correlated with the over-
activation of calpain 10. Based on these results, it was suggested that calpain 10 may 
be involved in the development of diabetic caractogenesis in male WBN/Kob rats 
(Sakamoto-Mizutani et al., 2002). Consistent with these results, the highest 
concentrations of calpain 10 were found in the water-insoluble fraction of lens tissues 
derived from a rat selenite cataract model, with over-activation of the enzyme 
detected in the lens cortex and epithelial cells, and coincident with the onset of 
cataractogenesis (Ma et al., 2001). However, whilst selenite-inducd cataract is 
known to involve the Ca2 induced over-activation of calpains, these cataracts are 
specifically located in the lens nucleus (Shearer et al., 1997) as opposed to the cortical 
location identified for calpain 10. In order to explain these results, it was observed 
that domain ifi of calpain 10 possesses a putative nuclear localisation signal and that 
the enzyme localises to the nucleus of aTN4-1 mouse cells, suggesting a role for 
calpain 10 in signal transduction (Ma et aL, 2001). Moreover, elevated Ca2 levels 
were found to enhance this nuclear localisation of calpain 10, and based on these 
combined results, it was suggested that the normal function of the enzyme may be in 
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epithelial cell differentiation but that elevated intracellular Ca 2 may lead to the 
increased uptake of calpain 10 into the nuclei of lens epithelial cells and a 
contribution to selenite cataract formation. Some support for this suggestion could 
come from the obsefvation that the highest levels of calpain 10 expression in the lens 
of non-diabetic mice were in regions of the lens associated with the differentiation of 
epithelial cells (Reed et ci., 2003). 
Clearly, the results described above imply that calpain 10 may be over-
activated in response to the elevated Ca 2 levels associated with lens cataract (Tang et 
al., 2003). Nonetheless, a requirement for Ca 2 by calpain 10 has not yet been 
definitively demonstrated (Reed etal., 2003) and the enzyme lacks domain IV of the 
typical calpains, which contains the EF-hand motifs generally believed to be 
responsible for calpain C a2tbinding 
 activities (figure 1.4; Reverter et ci., 2002; 
Reverter et ci., 2001a; Reverter et al., 2001b). However, it has been reported that 
TRA-3, a homologue of calpain 5 from Caenorhabditis elegans, which lacks EF-
hands, shows Ca 2 dependent proteolytic activity, (Sokol and Kuwabara, 2000). 
Moreover, domain ifi of TRA-3 is homologous to domain ifi of calpain 2, which has 
- recently been shown to possessti 2tbiii Iinfliiii5T(Tonipie[aF;2o0I1yVjwdin 
total, these results are suggestive of a role for calpain 10 in cataractOgenesis. Further 
investigation of this putative role would be particularly merited when it is considered 
that the lens opacification exhibited by WBNIKob rats is generally accepted as a good 
mimic of human diabetic cataract (Sakai, 1991). 
1.5.2 Calpain 3 splice variants: Lp85 and Lp82 
CAPN3 encodes calpain 3 and has been implicated in several genetic disorders 
(Huang and Wang, 2001), including muscular dystrophy (Jia et al., 2001; Gordon et 
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al., 2001; Richards et a]., 1999) and diabetes mellitus (Harris et al., 2003; Horikawa et 
aL, 2000). Multiple variants of CAPN3 have been described in rodents (Herasse et al., 
1999) and the best characterised of these at the protein level are the lens specific Lp82 
and Lp85 (Ma et al., 2000a). 
Lp82 has been localised to the nuclear and cortical regions of lens from new 
born mice (Ma et al., 2000b) and has been shown to co-localise with lens crystallins in 
the elongating fibres, and central fibres, of embryonic and post-natal mouse lenses 
(Reed et al., 2003). However, these latter studies that found in mature mouse lenses, 
levels of Lp82 were greatly reduced (Reed et al., 2003). It is known that the normal 
post-translational proteolytic processing of crystallins is completed prior to adulthood 
in mice (Ueda et a]., 2002a) and that this processing proceeds at a slower rate in the 
cortical fibres of adult murine lenses (David et al., 1994). Based on these 
observations, it was suggested that the normal function of Lp82 may be in the post-
translational processing of crystallins and that in adult mouse lenses, only low levels 
of the enzyme may be required in order to maintain crystalline architecture (Reed et 
al., 2003). 
- ----------
P}iü  
cataracts (Ma et al., 1999) and mouse lenses with congenital nuclear cataract, the 
presence of elevated Ca 2 levels leads to increased crystalline proteolysis by the 
enzyme (Baruch et al., 2001). Most recently, exogenous Ca2 was used to activate 
endogenous calpains in total soluble protein extracts from mouse lenses (Azuma et al., 
2002). These studies demonstrated that Lp82 was able to proteolyse czA-crystallin, a 
subunit of the a-crystallin multimeric protein complex (Horwitz, 20031 and 
additionally, that this proteolysis produced C-terminally truncated forms of cx.A-
crystallin with increased susceptibility to insolubilisation when compared to ctA- 
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crystallin proteolysis by other calpains, suggesting enhanced potential for Lp82 to 
induce cataracts (Azuma et cii., 2003). Based on these and other studies (Baruch et cii., 
2001) it has been proposed that Lp82 was the. major calpain involved in mouse 
cataract formation (Azuma et cii., 2003) 
Lp82 from rat lenses was found to be 99% homologous to its mouse 
counterpart (Ma et al., 1999), to be localised to the nuclear regions of the lens (Ma el 
cii., 2000a) and able to proteolyse crystallins (Ueda et al., 2002b). In these latter 
studies, total rat lens extraàts of soluble proteins were taken and endogenous calpain 
activity inhibited. It was then shown that exogenous Lp82 was able to proteolyse aA- 
crystallins, producing insoluble C-terminally truncated forms of the protein, the levels 
of which were enhanced by the addition of Ca 2t Moreover, these studies found that 
Lp82 produced a specific cleavage fragment, czA1.168, which has also been identified 
in the Lp82-mediated proteolysis of mouse aA-crystallins (Azuma et cii., 2003). This 
fragment lacks the final five C-terminal amino acid residues of czA-crystallin and the 
C-terminal region of this protein, u.A158173, is essential for its chaperone activity with 
- flncation of the aA158.173 region leading to lens cstallin agyegation, 
insolubilisation and cataract formation (Sharma et al., 1996; Takemoto, 1994). The 
studies of Ueda et cii., (2002b) further showed that in rat lenses, endogenous levels of 
insoluble C-terminally truncated ctA-crystallins were significantly enhanced under the 
elevated Ca2 conditions of selenite-induced cataract when compared to age-matched 
lenses from healthy non-diabetic rats. It was found that the highest proportions of 
these C-terminally truncated ciA-crystallins could be associated with Lp82 proteolysis 
and the Lp82 specific crystallin fragment aA 1 .168 whilst a similar selective 
insolubilisation of truncated crystallins was reported by other authors (Ueda et al., 
2002a). Based on these combined results, it was suggested that Lp82 may be the 
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major calpain involved in selenite cataract formation in rats (Ueda et cii., 2002b). 
However, these results contrast to those of other authors (Inomata et al., 2002) who 
studied Lp82-mediated crystallin proteolysis in Shumiya cataract rats (SCR5), which 
also demonstrate spontaneous nuclear cataract. These studies. demonstrated that Lp82 
activity occurred in both normal and cataractous lenses with no specific localisation to 
lens regions associated with cataract formation in SCRs. Taken with the results of 
other studies (Inomata et al., 2000), it was concluded by Inomata et al., (2002) that 
Lp82-mediated proteolysis made no direct contribution to cataractogenesis in SCRs 
Following on from this work, the effect of streptozotocin-induced diabetes (Perry, 
1987) on the Lp82-mediated proteolysis of rat lens crystallins in the absence of 
cataract was investigated (Thampi et cii., 2002). These diabetic rats were killed prior 
to the onset of cataract and C-terminal cleavage patterns of crystallins in water-
soluble fraction of their lenses analysed using electrospray ionisation mass 
spectrometry. It was found that levels of C-terminally truncated ctA-crystallins and 
ctB-crystallins were significantly higher in diabetic lenses than age-matched non-
diabetic lenses. Moreover, the level of the Lp82 specific crystalline fragment aA1.168 
was similar in both lens groups, whereas C-terminally truncated aA-crystallin 
fragments specific to other calpains were strongly represented in diabetic lenses but 
not those of non-diabetics. Based on these results, it was suggested that Lp82 was not 
the major calpain activated when the rats were under diabetic stress (Thampi et al., 
2002). This suggestion was strongly supported by the results of studies on male 
WBNIKob rats. Lp82 was detected in both the nucleus and cortex of lenses from these 
rats, but the proteolytic activity of the enzyme disappeared after three months, nine 
months before the spontaneous appearance of the hereditary diabetes exhibited by 
these rats. However, other calpains appeared to be specifically activated with the 
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onset of cataract when under diabetic stress (Sakamoto-Mizutani er cii., 2002). 
There is therefore some debate as to whether Lp82 is the major murine 
calpain involved in lens cell crystallin processing and cataractogenesis. Adding to the 
debate, the Lp82 specific crystalline fragment, aA1.163, has previously been identified 
in various other mammalian lenses (De Jong et al., 1981) and most recently, in bovine 
lenses, which led to the proposal that the enzyme may be the major calpain in these 
lenses (Ueda et al., 2001). Whilst both Lp82 and Lp85 are believed to be absent in 
human lenses (Fougerousse et al., 2000), studies on these enzymes may help to 
elucidate the roles played by calpains in human cataractogenesis. Moreover, it is 
interesting to note that crystallin fragments corresponding to specific Lp82 cleavage 
products from czA-crystallin (Lund et al., 1996; Takemoto et al., 1995) and 13-
crystallin (Colvis et al., 2000) have been detected in human lenses whilst those from 
y-crystallins have been identified in some human cataracts (Baruch a cii., 2001). 
Nonetheless, several studies have clearly shown that Lp82 does not appear to play a 
major role in murine diabetic cataractogenesis (Thampi et al., 2002; Sakamoto-
Mizutani et cii., 2002) and based on the current evidence, this calpain would not 
appear to be involved in human cataractogenesis. 
At present, research on Lp85 in relation to Lp82 appears to be limited. 
Immunolocalisation studies have shown low levels of Lp85 to be present in the lens 
fibre cells of developing and post natal mice but that these levels were greatly 
decreased in mature mouse lenses, consistent with calpain autolysis and over-
activation (Reed et al., 2003). It has also been shown that the proteolytic activity of 
Lp85 is Ca2tdependent (Ma et a]., 2000a) but presently no role for the enzyme in 
cataractogeneis has yet been established. Nonetheless, the intimate association of this 
calpain with lens processes suggests that this possibility should not be excluded. 
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Structural studies on Lp82 and Lp85 have shown that in relation to calpain 3, 
these enzymes lack the unique insert regions, IS1 and 152 (figure 1.4), and possess a 
new N-terminal region (AXI) encoded by an alternative exon (Herasse et al., 1999). 
In addition, Lp85 possesses a further alternative splice, which leads to the addition of 
a short segment to domain IV, the calpain Ca 2 - binding region (Ma et al, 2000a; Ma 
et al., 1998a). These structural changes appear to give Lp82 greater stability than wild 
type calpain 3 (Ma et al., 2000b) and studies on calpain 3 splice variants have 
suggested that the novel AX1 N-terminus of Lp82 and Lp85 may play an important 
role in the ocular tissues of rodents (Nakajima et al., 2001). Interestingly, these same 
studies isolated CAPN3 isoforms encoding the AXI region from human ocular tissue 
(Nalcajima et al., 2001). However, the functional significance of the structural 
differences shown between Lp82 and Lp85, and calpain 3, and whether these 
differences influence the Lp82 and Lp85 activation mechanisms, are currently 
unknown. 
1.5.3 Calpain 2 
Encoded by CAPN2, calpain 2 is the best characterised member of the calpain 
superfamily (001f et al., 2003). The enzyme is highly conserved across mammalian 
species (Daman et al., 2000) and has been implicated in a range of pathological 
conditions (Huang and Wang, 2001), ranging from spinal cord injury (Ray et al., 
2003) to Alzheimers disease (DiRosa et al., 2002). However, over the last two 
decades, mounting evidence from numerous studies has suggested that the enzyme is 
involved in cataractogenesis. Earlier investigations established the ability of calpain 2 
to proteolyse a-crystallins and f3-crystallins and that calpain inhibitors could prevent 
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the progression of rodent cataract, which had been induced by the activation of 
calpain 2 in response to elevated Ca 2 levels. Based on these (Shearer, 2000; Azuma 
et al., 1997; Andersson et al., 1996, Shearer and Davis, 1991) and more recent studies 
Goll et al., 2003; Inomata et al., 2000), it is now generally accepted that calpain 2 
plays a major role in rodent lens opacification. Most recently, calpain 2 has been 
shown to similarly induce cataractogenesis, and to cleave crystallins, in the lenses of a 
variety of other mammalian species including: mice and guinea-pigs (Ueda et al., 
2002a; Ueda et al., 2002b; Fukiage et al., 1997), monkeys and rabbits (Nakajima et 
al., 2001) and calves (Ijeda et al., 2001). Nonetheless, a role for calpain 2 in human 
cataractogeneisis has not been definitively demonstrated, although the available 
evidence is strongly suggestive. The presence of calpain 2 in human lenses is 
generally accepted whilst Andersson et al., (1994) showed that the enzyme was the 
major calpain in the epithelial cells of human lenses exhibiting age-related cortical 
cataract. Human lenses with cortical cataract are known to have increased levels of 
intracellular Ca2 (Duncan and Bushell, 1975) whilst treating these lenses with 
extracellular Ca 2 leads to discrete cortical cataracts (Hightower and Farnum, 1985). 
The activity of calpain 2 has previously been demonstrated in the cortex of human 
lenses (David et al., 1989) but it was only recently, that the Ca2tinduced 
 activation of 
calpain 2 in this type of human cataract was demonstrated under physiologically 
relevant conditions (Sanderson et al., 2000). It was shown that when Ca 2 overload 
was induced incultured human lenses using ionomycin and physiologically relevant 
extracellular Ca 2 
 concentrations, cortical opacification resulted, accompanied by a 
significant loss of crystallins from the soluble fraction of the lens. These effects were 
strongly inhibited when extracellular Ca 2 was chelated with EGTA. Moreover, 
analysis of the insoluble fraction from human lenses showed that elevated Ca 2 levels 
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had led to high levels of vimentin proteolysis. Vimentin is a cytoskeletal protein 
substrate of calpain 2 in the lens, and other tissues, and vimentin proteolysis is taken 
as a biomarker of calpain 2 activation (Goll et al., 2003). Previous studies on animal 
lenses have shown that elevated Ca 2 levels lead to almost total degradation of 
vimentin but that this effect can be strongly reduced by calpain inhibitors (Sanderson 
et al., 1996; Marcantonio et al., 1991). Taken overall, these results clearly imply that 
calpain 2 plays a role in at least cortical human cataractogenesis. 
Sevethl studies have strongly suggested that calpain 2 is the major calpain 
activated in murine diabetic cataractogenesis. Sakamoto-Mizutani et al., (2002) 
showed that in spontaneously diabetic male WBN/Kob rats, the onset of 
cataractogenesis was accompanied by increased levels of proteolytic activity due to 
the specific activation of calpain 2. Moreover, Thampi et al., (2002) showed that there 
were high levels of the ciA-crystalline cleavage fragment, ct-A1. 1 62, which is specific 
to calpain 2, in the diabetic lenses of streptozotocin-treated rats but that the fragment 
was absent from the lenses of age-matched non-diabetic rats. In studies on human 
lenses, these latter authors showed that levels of C-terminally truncated ciA-crystallins 
were significantly higher in diabetic cataracts than in age-matched non-diabetic 
cataracts but were not able to ascribe the crystalline cleavage sites to calpains. In 
addition, other studies have shown that cxA-crystallin chaperone activity is strongly 
decreased in human diabetic cataracts with these levels of activity less than in age-
matched senile human cataracts (Cherian-Shaw et al., 1999; Cherian and Abraham, 
1995; Thampi and Zarina, 2002). At present there appears to be no clear 
demonstration of calpain 2 activity in diabetic lenses. However, it is known that 
calpain activity in normal human lenses is low, circa 3% of that in rat lenses (David et 
al., 1989) and most recently it has been shown that overall levels of Ca 2 found in the 
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lenses of diabetic cataract are statistically no different to those of normal lenses, 
implying that the elevated levels of Ca 2 known to be associated with diabetic cataract 
maybe highly localised to specific lens regions (Tang et al., 2003). 
1.5.3.1 The activation of calpain 2 
Despite many years of intensive study, full details of the C a2tmedi ated 
activation of calpain 2 have not been elucidated (Goll et al., 2003; Perrin and 
Huttenlocher, 2002). Some progress was made in this direction when the recently 
solved crystal structures of Ca 2 free, rat calpain 2 (Hosuield et al., 1999) and human 
calpain 2 (Strobl et al, 2000) suggested a structural basis for the Ca 2 dependence of 
the enzyme. These studies confirmed the dimeric nature of the enzyme, which 
possesses an 80 kDa large subunit with the four domain organisation (I, II, ifi and IV) 
of typical calpains, and a 30 kDA smaller regulatory subunit comprising domains VI 
and V (figure 1.4; Sorjmachi and Suzuki, 2001). Moreover, the high-resolution data 
provided by the studies of Strobl et al, (2000) and Hosfield et al., (1999) revealed that 
- 
sub-domains, Ha and llb. Between them, these sub-domains contain the amino acid 
residues necessary to form this site (Figure 1.5) but in the absence of Ca 2t structural 
constraints hold these subdomains apart, thus maintaining the active site in a 
disassembled state. The N-terminal segment of domain I appears to anchor domain Ha 
to domain VI in the regulatory subunit whilst Domain llb makes a number of contacts 
with domain ifi, which is centrally placed within the molecule, making contact with 
each other domain of the enzyme. Effectively circularising the inactive catalytic 
subunit, domain ifi is connected via a short linker to Domain IV, which, in turn 
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associates with domain IV of the regulatory subunit (Strob] et al., 2000; Hosfie]d et 
al., 1999). This association of domains IV and VI has previously been shown to 
proceed via predominantly hydrophobic interactions and facilitates the hetero-
dimerisation of the calpain subunits (Blanchard a al., 1997; Lin a al., 1997). Based 
on these results, a number of authors have proposed mechanisms for core events 
involved in the Ca2tmediated 
 activation of calpain 2 (Figure 1.5; Reverter et al., 
2001a; Reverter a aL, 2001b; Strob] a al., 2000; Hosfield et al., 1999). Essentially, 
these mechanisms propose that Ca 2 binds to domains IV and VI, which each contain 
Ca2 binding sites consisting of a series of linked ct-helices forming potential EF-hand 
motifs (Dutt a al., 2000; Kretsinger, 1997). This binding induces conformational 
changes in domains IV and VI, which leads to release of the domain I N-terminal 
anchor and initiates a series of structural events, including conformational changes, 
resulting in the realignment of domains Ha and Jib and the assembly of the calpain 2 
papain-like cysteine protease domain (figure 1.6; Reverter et al., 2002; Reverter et al., 
2001a; Reverter a al., 2001b; Strobl a al., 2000; Hosfield et al., 1999). Additionally, 
whilst generally supporting this proposed mechanism, several studies have indicated 
-  the possibility that Ca 2 binding to domain II and domain Ill may also play a role in 
the activation of calpain 2 (Hata et al., 2001; Tompa et al., 2001; Moldoveanu et al., 
2001; Hosfield et al., 2001). 
Whilst the above results provide insight into the internal molecular events 
involved in the activation of calpain 2, an important need with regards to external 
environmental events associated with activation of the enzyme is clear elucidation of 
the threshold levels of Ca 2 required for this activation. Under normal lens cell 
condition, where Ca 2 ]evels are in the nanomolar range, calpain 2 exists as an 
inactive proenzyme (Azuma et al.; 1997) and several models have been proposed for 
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the Ca2tmediated trigger used by the enzyme for activation. It has been postulated 
that calpain 2 activation may involve a "calpain cascade" in which 
Figure 1.5 The Ca2 dependence of calpain 2 activation 
Figure 1.5 was adapted from Biswas et al., (2004) and is a representation of core 
events, which form the basis of the calpain 2 dependence on Ca 2 for activation. 
Figure iSA shows calpain 2 with subdomains ila and llb, distal and thus, the 
enzyme's active site in a disassembled state. Figure 1.513 shows Ca 2 binding to EF 
hands in domain VI, which disrupts a salt bridge between lysine 7 of domain I of the 
catalytic subunit and asparagine 154 of domain VI of the smaller subunit. Disruption 
of-this-salt-bridge--facilitates--the--liberation--of--the-N-teminal-region---of-domain--I, 
thereby initiating a series of structural movements that bring domain llb into close 
proximity with domain ila and assembly of the calpain 2 active site, represented in 
figure 1.513 by cysteine 105 and histidine 262. These processes may be assisted by 
Ca2 binding to acidic residues on both sides of the active site and lipid / membrane 
mediated Ca2 binding to an acidic loop in domain M. Also associated with the lipid / - 
membrane mediated activation of calpain 2 is Ca 2 binding to domain IV (figure 
1.513), which works in concert with the above Ca 2 binding events to promote other 
features of the enzyme's activation process, including autolysis and subunit 
dissociation (figure 1.6, Azuma et al., 1997). Additionally, figure 1.513 shows that 
domain V of calpain 2 (in white) has a surface location, which would give this region 
access to lipid bodies / the membrane, consistent with the recent proposal that a 
membrane interactive a-helix within domain V may play a role in calpain 2 activation 
(Brandenberg et al., 2002). 
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calpain 1, which is activated in the presence of j.tmolar Ca 2t proteolyses calpain 2, 
thereby reducing its Ca 2 requirement to a level that would permit the latter calpain to 
be active at physiological levels of Ca 2 (Tompa et al., 1996). However, more recent 
studies showed that calpain 1 caused no detectable proteolytic degradation of calpafn 
2 and did not change the Ca 2 concentration required for the proteolytic activity of 
calpain 2. It was concluded that calpain I was unlikely to act as an activator of calpain 
2 in living cells (Thompson et al., 2000). Croall and Demartino, (1991), proposed the 
autolytic model of calpain 2 activation (Figure 1.6). According to this model, 
increases in intracellular Ca2 trigger the autolytic cleavage of N-terminal segments 
from domain I and domain V of calpain 2. These structural modifications then lead to 
conformational change in the calpain molecule and separation of the truncated 
subunits, accompanied by activation of the enzyme (Johnson and Guttmann, 1997; 
Azuma et al., 1997). However, there are several difficulties associated with this 
model. The autolysis of domain V of calpain 2 involves the cleavage of the 86 N-
terminal residues from the enzyme's smaller subunit. This cleavage does not affect the 
enzyme's Ca2 requirement and its significance is not well understood (RIce et al., 
1997a). In contrast, it is well established that cleavage after residue 9 of domain I of 
the enzyme's larger subunit, and later possibly after residue 19, greatly reduce the 
enzyme's Ca 2 requirement for activation (Goll et al., 1992). However, a number of 
studies have shown that autolysis of the domain I N-terminal segment is neither 
strictly necessary for activity (Molinari et cii., 1994) nor sufficient for activation (RIce 
et cii., 1997b). Furthermore, how the autolysis model of calpain 2 activation would be 
triggered under normal in vivo conditions is unclear. It is well established that, in 
vitro, calpain 2 requires levels of Ca 2 in the mM range for activation (Pen-in and 
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Huttenlocher, 2002) and clearly, these levels of Ca 2 do not occur in normal cellular 
metabolism, which are generally !~ 1 Rmolar (Goll et al., 1992). One possible 
explanation has been proposed by Azuma et al., (1997) who suggested that transient, 
regionally specific elevations in Ca 2 may activate calpain 2. Nonetheless, taken 
overall, these results suggested that in addition to autolysis, some other factor(s) are 
involved in the in vivo activation of calpain 2. As described above, membrane-
associated forms of calpain 2 have been detected in the lens and it has been shown 
that lipid can lower the Ca 2 requirement for activation of the enzyme to near 
physiological levels (Shearer, 2000; Azuma et al., 1997). Based on these observations, 
Mellgren (1987) proposed the membrane activation model for calpain 2. The original 
model proposed by the latter author has since been developed to account for more 
recent data and is shown in its present form in Figure 1.6. The model shown in Figure 
1.6 indicates that elevated intracellular Ca 2 triggers the translocation of calpain 2 
from the cytosol to the membrane. There, at physiological levels of Ca 2 and the 
presence of membrane effectors such as specific phospholipids, the dissociation of the 
calpain 2 subunits is promoted, accompanied by activation of the enzyme. Once so 
activated on the membrane, calpain may diffuse into the cytosol or maybe confined to 
acting on mmbrane-associated proteins (Molinari and Carafoli, 1997, Kawasaki and 
Kawashima, 1996). Whilst a generally accepted model, there is some debate with 
regards to events involved in the membrane activation model of calpain 2. Some 
authors have disputed the involvement of subunit dissociation in the activation of the 
enzyme (Dutt et al., 1998; Elce et al., 1997a; Zheng and Mellgren, 1996). Other 
studies would support the view that the subunit dissociation of calpain 2 is 
accompanied by autolysis, producing the N-terminally truncated large subunit of the 
enzyme as the active species (Dainese et aL, 2002; Nakagawa et al., 2001; Kitagaki et 
Oil 
al., 2000). Yet other studies would suggest that subunit dissociation occurs without 
autolysis and that the intact lone large subunit is the enzymatically active form of 
calpain 2 (Cottin et al., 2001; Pal et al., 2001; Bessiere et al., 1999; Yoshizawa et al., 
1995). At present, whilst subunit dissociation is generally accepted as a feature of 
Figure 1.6 Activation pathways of calpain 2 
30
- 	
Dsniensanon' 	 ica2+ RS 
cs 	
Active species 
+ D Function? 
Hydrolysis 	 18 [ Rc; 
on 	
kDa 
Dissociation 	 18 
Traiislocation to 
	 2+ 
 /Acuvau 	
MEMBRANE 	 +
W. membrane 	
Ca2 , activator? 	 Substrate 	
t 
Cal 
•ca] 	 Autolysis 	 [ 	 B'+]  Dissociatio,i 	 + I kfla• kDa- 	 kila 	 kDa LIED 80 	 ICa2+ Active species 
Lipid I membrane 	 Ca't activator? 
Ca't activator? 	 MEMBRANE 
Figure 1.6 shows a schematic representation of the membrane mediated activation of 
calpain 2 and was adapted from Suzuki and Sorimachi (1998). In the presence of 
elevatedintracellularCat, xIimericcalpain. 2(1)JstranslQcatd_tqthemembrapt(2) 
Then, in the presence of lipid I Ca2 / activators(?) subunit dissociation occurs, either 
directly and leading to the formation of the activated 80 kDa form of calpain 2 (5), or 
preceded by autolysis and leading to the activated 76 kDa form of the enzyme (4). It 
has been suggested that an end product of both forms of activation may be the 
dimerisation of liberated calpain 2 small subunits. 
calpain 2 activation, no proposed mechanism of activation for the enzyme has been 
definitively rejected. Indeed, it has been suggested that calpain 2 may employ more 
than one activation mechanism with choice depending upon cellular conditions 
(Figure 1.6; Sorimach and Suzuki, 1998; Azuma et al., 1997). A number of recent 
studies have progressed understanding of the membrane activation model for calpain 
2. Domain ILl of the enzyme was found to contain an EF hand motif and was shown to 
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bind lipid in a Ca2 dependent manner (Tompa et al., 2001). Moreover, this domain 
was shown to form an anti-parallel (3-sheet sandwich, which is structurally related to 
C2 domains (Strobi et al., 2000; Hosfield et al., 1999) and believed to modulate 
enzyme activity via Ca2 regulated lipid.binding (Rizo and Sudhof, 1998). It has been 
proposed that a similar mechanism may allow domain 111 to modulate the activation of 
calpain 2 via electrostatic interactions with domain II (Reverter et al., 2002; Reverter 
et al., 2001a; Reverter et al., 2001b). Domain V of calpain 2 was shown to possess a 
C-terminal segment with the sequence G 1 7TAMRILGG, which appeared to be 
required for the lipid activation of calpain 2 (Crawford et aL, 1990). More recent 
investigations, using peptides homologous to various regions of domain V, 
demonstrated that although the presence of the TAIvIRIL sequence was required for 
these lipid interactions, the presence of a polyglycine sequence was also necessary for 
such interaction (Arthur and Crawford, 1996). It was concluded by these latter authors 
that their data supported the general membrane activation model proposed for calpain 
2 (Figure 1.6; Suzuki and Sorimachi, 1998) but no further investigations into the lipid 
I membrane interactions of these domain V segments appears to have been performed. 
1.6 Calpain inhibitors and cataract 
In view of the major role played by calpains in cataractogenesis, a number of 
authors have suggested that calpain inhibitors may have potential as anti-cataract 
agents (Biswas et a]., 2001; Donkor, 2000; Wang and Yuen, 1994. However, to 
perform this function, these inhibitors must possess a number of characteristics, 
including high specificity for lens calpains, water solubility and membrane 
permeability. The only known compound with absolute specificity for calpains is their 
endogenous inhibitor, calpastatin (Todd et al., 2003) but due to its high molecular 
mass, and thus membrane impermeability, this inhibitor is of little therapeutic use 
(Goll et al., 2003). In response, calpain inhibitors have been derived from naturally 
occurring sources and produced by both semi-synthetic and fully synthetic routes 
(Hernandez and Rousch, 2003; Ray et al., 2003; Donkor, 2000; Wells and Bihovsky, 
1998; Chatterjee, 1998). Amongst the best characterised of first generation calpain 
inhibitors are the epoxysuccinyl peptides, which include E64 and its analogues 
(Figure 1.7; Wang and Yuen, 1994; Azuma et al., 1992). These inhibitors possess 
electrophilic centres within their structure that form an irreversible covalent bond with 
the thiol group of the cysteine residue in the calpain active site, thereby blocking 
calpain proteolytic action (Wang, 1990, Parkes et al., 1985). E64 was found to show 
some ability to reduce the proteolysis of 3-crystallins and retard cataractogenesis in 
rodent models (Lampi et al., 1992; Azuma et al., 1992) but showed poor selectivity 
for calpain, inhibiting other cysteine proteases, and suffered from poor membrane 
permeability due to the presence of charged carboxylate and guanidinium groups 
within its structure (Wang and Yuen, 1994). The esterification of the E64 carboxyl 
- group and the modification of the compound's guanidinobutane group to an alkyl 
group produced E64d, which showed improved membrane permeability. Moreoever, 
in viva, E64d is readily hydrolysed by cellular esterases to an active form, which has 
been shown to prevent induced-cataract in lens culture models (Ray et al., 2003; 
Azuma et al., 1992). A further well characterised class of first generation calpain 
inhibitors are the peptide aldehydes, which bind calpains in a reversible Ca 2 -
dependent manner and include leupeptin, calpain inhibitor I, calpain inhibitor II 
calpeptin (Iqbal et al., 1997) and MDL28170 (Wang and Yuen, 1994). Electrophilic 
centres within these inhibitors, usually a functional group such as an aldehyde or a 
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ketone, which contains a carbonyl moiety, react with the thiol group of the active site 
cysteine of calpains. These reactions form covalent hemithioacetal or hemithioketal 
adducts, which effectively allows these peptide aldehydes to function as competitive 
inhibitors of calpains (Wang, 1990). The peptide aldehydes showed improved 
membrane permeability and calpain selectivity over E64 and its analogues and 
demonstrated some success in retarding calpain-mediated cataractogenesis (Azuma et 
al., 1992). However, low water solubility and toxicity to lenses largely prohibited 
their use as pharmacological tools and anti-cataract agents (Biswas et al., 2001; 
Sanderson, 1996; Lampi et al., 1992). 
As potential therapeutic agents in a variety of disorders, the problems of poor 
membrane permeability and calpain selectivity have led to the development of a large 
number of novel compounds directed against calpains (Ray et al., 2003; Di Rosa et 
al., 2002; Wang and Yuen, 1994) and indeed cysteine proteases in general (Hernandez 
and Rousch, 2003). These efforts have produced a chemically diverse range of novel 
compounds, including: reversible calpain inhibitors such as peptidyl aldehydes, a-
ketocarbonyls and cz-ketoamides, and irreversible calpain inhibitors such as 
fluoromethylketones, vinyl sulphones, diazomethylketones, acyloxymethylketones, 
sulphoniuminethylketones, haloacylhydrazines and epoxysuccinyl peptides 
(Hernandez and Rousch, 2003; Ray et al., 2003; Donkor, 2000; Wells and Bihovsky, 
1998). As recent examples: Novel compounds, based on short peptides with 
heterocyclic components bearing aji-unsaturated carbonyl functionalities have been 
shown to be potent calpain inhibitors (Mann et al., 2002). Several authors have 
employed a peptidyl a-hydroxamate scaffold for the design of reversible calpain 
inhibitors and identified a hydroxamate with an N-alkoxy substituent that enhanced 
inhibitory potency by strengthening the hydrogen bonding between the hydroxamate 
Ga 
NH moiety and residues in the active site of calpain (Josef et al., 2001; Donkor et al., 
2001). Peptidyl methyl ketone inhibitors have been designed using 1-
hydroxybenzotriazole and other peptide-coupling reagents to produce a number of 
compounds, which are potent irreversible inhibitors of the enzyme (Tripathy et al., 
2000). Calpastatin has been used as a structural template and it was found that the 
fusion of an eleven poly-arginine peptide to the inhibitor yielded a peptide with 
enhanced membrane permeability but no reduction in its ability to inhibit calpains 
when compared to naturally occurring calpastatin (Wu et al., 2003). Peptidomimetics 
have been introduced into the design of reversible calpain inhibitors. The substitution 
of peptide constituent amino acid residues with piperidine carboxamides or 
benzothiazine led to the identification of novel ketoamide and aldehyde inhibitors of 
calpains with high selectivity over other cysteine proteases (Lubisch et al., 2000; 
Wells et al., 2001). A number of non-peptide calpain inhibitors have been developed 
and recently, a—mercapto acrylate derivatives have been synthesised, which interact 
with the Ca2tbinding 
 domains ifi, IV and VI rather than the active site of calpain 
(Lin et al., 1997; Wang et al., 1996). One such derivative, PD150606, was reported to 
be highly membrane permeable and highly selective for the inhibition of calpains 
relative to other cysteine proteases (Wang et al., 1996), although more recently, the 
compound has been shown to inhibit motor neuron death via inhibition of kainate-
induced Ca2 influx and not via calpain inhibition (Van den Bosch et aL, 2002). 
In general, the testing of these novel calpain inhibitors as anti-cataract agents 
is in the infancy stage. Nonetheless, the lessons being learnt, coupled to the recently 
gained insights into calpain activation mechanisms (Reverter et al., 2001a; Reverter et 
al., 2001b; Strobl et al., 2000; Hosfield et al., 1999), will allow structure based 
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inhibitor design (Hernandez and Rousch, 2003) and the production of highly specific 
lens calpain inhibitors with physiochemical properties tailored for lens entry. 
1.7 CONCLUSIONS 
Here, an overview of current research into the role of calpains in 
cataractogenesis has been described and the body of evidence strongly suggests that 
these enzymes participate in the eye disorder. In murine lenses, and possibly those of 
other animals, calpain 2 and Lp82 are the major candidates for these roles with the 
possibility of contributions from calpain 10 and Lp85. Calpain 2 appears to be the 
major calpain involved in animal models of diabetic cataractogenesis. Lp82 and Lp85 
have not been detected in human lenses and it is tempting to extrapolate from animal 
models and suggest that calpain 2 may play a major role in at least some forms of 
human cataractogenesis. 
- - 
	 As ytiio definitive -mechanism(s) forthe activation - of- calpain-2-unde---------------- 
physiological conditions appears to have been presented although the involvement of 
lipid / membranes in these mechanisms seems probable and it is worthy of note that 
high levels of Ca2tinduced calpain 2 activity have been demonstrated in the 
membrane fraction of human lenses (Sanderson et al., 2000). In response to 
physiologically relevant elevations of lens Ca 2t there appears to be the possibility of 
multiple mechanisms of calpain 2 activation, leading to different enzymatically active 
forms of the enzyme. It would seem that the mechanism of calpain 2 activation used 
depends at least in part, upon the cellular location of the enzyme. It may be that in the 
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lens, physiological functions are performed by different isoforms of calpain 2, 
generated according to the location of the enzyme's activation. However, under 
pathological conditions such as cataract where intracellular levels of Ca 2 are in the 
niN'l range and above (Tang et al., 2001), autolysed forms of calpain 2 have been 
consistently detected (GoB et al., 2003; Shearer, 2000; Azuma et al., 1997). These 
observations clearly suggest that pathological levels of Ca 2 are able to directly induce 
the activation of calpain 2 via autolytic mechanisms. Nonetheless, it has been 
observed that pathological levels of lens Ca 2 are also likely to directly induce the 
conformational changes associated with the production of non-autolysed forms of 
activated calpain 2 (Shearer, 2000; Azuma et al., 1997). It may therefore be that in 
cataract, multiple mechanisms of calpain 2 activation lead to the unregulated 
proteolysis of crystallins and lens opacification. 
1.8 Aims of the study and Scope of the work 
The aim of this study was to develop an in vitro model of cataract in order to 
tiiij the ãdt inhibitors  ösiHëthëiEilityMCa2 -_ 
to induce cataractogenesis in porcine lenses is investigated for the first time, 
extending the range of in vitro lens sources available for such studies. Atomic 
adsorption spectroscopy is used to investigate the relationship between levels of 
porcine lens Ca2 and degree of opacification within these lenses whilst calpain 
inhibitors are used to confirm the participation of calpains in this opacification 
(chapter 2). 
These investigations imply a role for calpain 2 in porcine cataract and the 
remaining work presented in this thesis attempts to extend the understanding of the 
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role played by lipid / membranes in the lens activation of this enzyme corroborating 
the hypothesis that membrane phospholipids play a significant ro]e in the activation of 
calpain 2 in vivo. Hydrophobic moment plot based methodologies, hydropathy 
analysis and the DWIH measure of membrane interactive potential are used to 
identify segments within the primary structure of domain V of calpain 2 for the 
potential to form lipid interactive secondary structure (chapter 3). 
A peptide homologue of the domain V segments thus identified is then tested 
experimentally for the ability to penetrate membranes, using haemolytic analysis and 
monolayer studies. Additionally, the ability of the peptide to adopt lipid interactive 
secondary structure is investigated in conjunction with German collaborators using 
FTIR conformational analyses (chapter 4). 
A role for domain V of calpain 2 in the membrane mediated activation of the 
enzyme is then investigated. The large subunit of calpain 2 (LS-calpain 2) is 
proteolytically active in the absence of the calpain 2 small subunit. LS-calpain 2 and 
calpain 2 are assayed for proteolytic activity in the presence of various phospholipids 
in order to see if these lipids can reduce the threshold Ca 2 requirement of these 
- - enzymes, which is clearly demonstrated for calpain 2 but not LS-calpain 2. In 
addition, the lipid preferences of calpain 2 are investigated using monolayer studies 
(chapter 5). 
In combination, the results of these studies are used to construct a putative 
model for the lipid / membrane activation of calpain 2 and in the discussion of the 
potential of calpain inhibitors to act as anti-cataract agents (chapter 6). 
CHAPTER 2 
The in vitro ability of the peptide aldehyde, SJA6017, 
to inhibit calpain-mediated porcine opacification 
Biswäs, S., Harris, F., Singh, J. and Phoenix, D. A. (2003) The in vitro ability of the 
peptide aldehyde, SJA6017, to inhibit calpain-mediated porcine cataractogenesis. 
Cell. Mol. Biochem. In press 
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2.1 ABSTRACT 
Calpain inhibitors show the potential to support non-surgical alternatives in 
treating cataract. Here, the recently developed calpain inhibitor, SJA6017, and calpain 
inhibitor II are tested in vitro for their ability to inhibit opacification in porcine lenses. 
These lenses were incubated in increasing levels of extra-lenticular Ca 2 (5 mlvi - 30 
mlvi). Atomic absorption spectroscopy was used to determine the total Ca 2 content of 
these lenses and a correlation between lens Ca 2 uptake and levels of lens 
opacification was found with a lens total Ca 2 content of the order of 5.0 ltmoles Ca2 
(gm wet lens weight)1 
 corresponding to the onset of opacification. A total lens Ca 2 
content of the order of 8.0 jimoles Ca 2 (gm wet lens weight) - ' corresponded to 
opacity occupying approximately 70% of the lens cell volume. This degree of 
opacification was reduced by approximately 40%, when SJA6017 (final concentration 
0.8 pJvi) was included in the extra-lenticular medium, suggesting that the Ca 2 - 
mediated activation of calpains may be involved in the observed opacification. 
Supporting this suggestion atomic absorption spectroscopy showed that the effect of 
SJA601l .(finaLconcenträtion_0.84tMonJensopacification was not çipc_to  the 
compound restricting porcine lens Ca 2 uptake. Calpain inhibitor II showed no ability 
to retard porcine opacification and the results of this study are discussed in relation to 
the development of SJA6017 as an anti-cataract agent. 
Irl 
2.2 INTRODUCTION 
With the realisation that calpains are involved in a spectrum of human 
disorders, investigation into the potential of calpain inhibitors to act as therapeutic 
agents has led to the production of a plethora of agents (section 1.6). One of the most 
potent of these agents is the recently characterised compound, SJA6017 (figure 2.1; 
Nakamura et al., 2003; Fukiage et al., 1997). 
Figure 2.1 The chemical structure of SJA6017 
F, O O 	 CHO 
Figure 2.1 was adapted from Nakamura et al., (2003) and shows the chemical 
struififëfthr recentlycharacterisedcalpain —inhibitorr--SJA601-7--(N-@-
fluorophenylsulfonyl)- L-valyl-L-leucinal), which is essentially a peptide aldehyde. The 
functional aldehyde of the compound (in bold) forms a hemithioacetal with the active 
SH on the cysteine residue of calpains, thereby reversibly inhibiting the proteolytic 
activity of the enzyme (section 1.6; Inoue et al., 2003; Fukiage et al., 1997). 
The chemical structure of SJA6017 is shown in figure 2.1 and it can be seen 
that the inhibitor is a peptide aldehyde. Essentially, SJA6017 was synthesised by 
treating L-vahne with 4-fluorobenzenesulfonyl chloride to give N-(4-
fluorophenylsulfonyl)- L-valine. This product was then coupled with L-leucinol and the 
resulting compound oxidised, using a sulphur trioxide-pyridine complex, to give N-
(4-fluoropheny!su1fonyl)- L-valyl--leucinal (Fukiage et al., 1997). SJA6017 has been 
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shown to be a potent inhibitor of calpain 2 (Nakamura et al., 1999; Fukiage et 
al.1997) and Lp82 (Nakamura et al., 1999). In relation to other calpain inhibitors, 
SJA6017 shows high specificity for calpains, exhibiting only limited efficacy against 
other cysteine proteases and relatively low cytotoxicity (Inoue et al., 2003). Based on 
these therapeutically desirable characteristics, SJA6017 has been studied as a potential 
agent for the treatment of a variety of human disorders including: brain injury (Ray et 
al., 2002; Kupina et al., 2001), Alzheimers disease (DiRosa et al., 2002), retinal cell 
damage (Tamada et al., 2002) and angiogenesis (Tamada et al., 2000). Additionally, 
SJA6017 is one of the few recently developed calpain inhibitors to be tested as an 
anti-cataract agent. Studies on rats showed that systemic 5JA6017 was taken up by 
the lens and inhibited in vivo selenite cataract formation (Tamada et al., 2001) whilst 
studies on cultured lenses from rats (Mathur et al., 2000; Fukiage et al., 1997), guinea 
pigs and rabbits (Fukiage et al., 1998) have found the inhibitor to possess high 
efficacy in preventing Ca2tinduced 
 models of cataract. There appears to have been no 
investigation into the effects of SJA6017 on calpain-mediated cataractogenesis in 
other mammalian lenses and in terms of physical dimensions, porcine lenses are close 
Lo hth Ises1 In hepnta5i,the 1ff Vit abilityofSfAóoi7yand-the well--------- - -- - 
characterised calpain inhibitor, calpain inhibitor H, to inhibit C a2tinduced 
opacification in porcine lenses was investigated. To ensure that this ability was not 
related to reduced lens cell uptake of Ca 2t the total Ca 2 content of opacified lenses, 
which had been treated with, either SJA6017 or calpain inhibitor II, and their 
corresponding controls, were determined using atomic absorption spectroscopy. The 
results of these studies showed that neither calpain inhibitor H nor SJA6017 were able 
to significantly influence porcine lens cell uptake of Ca 2 and that SJA6017 alone 
retarded opacification in these lenses. 
E1 
2.3 MATERIALS AND METHODS 
2.3.1 Materials 
The calpain inhibitor, SJA6017, was donated by Senju Pharmaceuticals 
(Japan). Calpain inhibitor H and Analar calcium chloride were purchased frdm Sigma 
(UK). All other reagents were of Analar grade with Ca 2 <0.01 ppm and purchased 
from Sigma (UK) except for concentrated nitric acid (70%, w/v) and lanthanum 
chloride, which were purchased from Fischer (UK). Aliquots (1 litre) of lens medium 
(LM) were prepared: A solution containing: NaCl, 137 mlvi; KC1, 12.7 mM; NaHCO3, 
12mM; NaH2PO4, 36 mM; Tris, 10 mlvi, pH 7.5 was autoclaved. The cooled solution 
was supplemented with: penicillin (final concentration 100 units ml'), streptomycin 
(final concentration 100 units mY 1 ) and sterile glucose solution to give a final glucose 
concentration of 5.5 mM. The tonicity of the resulting mixture was adjusted to give a 
value of 300 mOsm Kg' according to Varma et al., (1986). 
2.3.2 Lens photography 
Lenses were photographed with their epithelial side up using an SLR camera 
(Nikon 55 with micro-lens attachment) against a black grid with homogeneous retro-
illumination from a light table. When viewed through a transparent lens, the black 
grid should be visible without any discontinuity of the lines. However, since the 
porcine lens has a somewhat biconvex shape (as most other lenses), clear visibility of 
a plane grid was only obtained through the relatively central area of the lens. Some 
parts of the grid will therefore appear distorted or blurred in the periphery of even a 
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clear lens. In addition, some optical irregularity is always seen in a natural lens, and 
being a biological tissue, a lens is never totally transparent. Opacification was 
determined qualitatively by assessing the loss of visibility of the grids, either as an 
overall diffuse blurring, segmental discontinuity of the lines or a total loss of visibility 
when viewed through the central circular area of the lens, as well as the appearance of 
white patches within the lens substance. The results are presented as original 
photographs in figures 2.3, 2.4, 2.5 and 2.7. 
2.3.3 Isolation of the porcine whole lens system and preliminary analyses 
Paired porcine eyes were obtained from a local abattoir (Preston Meats, UK) 
and washed with sterile saline (0.25 mlvi) containing 1% (wlv) povidone-iodine. 
Under aseptic conditions, the lenses of these eyes were removed by gentle dissection 
from the posterior approach to avoid anterior epithelial damage (Holleschau et al., 
1986). Lenses were visually examined and those obviously damaged, or clearly 
showing pre-existing cataracts were rejected (Figure 2.3A), including the matching 
lsiwtlteyair: Thasekctdpairs ofrnatchedienseswere
-then-cleaned-of-acmerent ---- -- - - - - - 
vitreous material, iris pigment and lens zonules, and immediately weighed. Each lens 
was placed on its posterior side and photographed as described above. 
Preliminary experiments were performed to optimise experimental conditions 
such that the Ca 2tmediated induction of porcine lens opacification reached desired 
levels without accompanying lens degradation. Accordingly, a series of matched lens 
pairs were taken and one lens from each pair immersed in 2 ml of sterile LM. The 
remaining lenses from the matched lens pairs were similarly placed in LM except that 
in this case, the medium contained sterile calcium chloride with concentrations that 
varied between 5 mM and 30 mM. These samples were then incubated at either: 25°C 
or 30°C for either: 12, 15, 18 or 24 hr, lens integrity visually assessed and optimal 
conditions for lens incubation determined. 
2.3.4 The effect of calpain inhibitors on porcine lens opacification 
A series of matched porcine lens pairs were taken and one lens from each 
matched lens pair was incubated in sterile LM containing CaCl2 with a concentration 
of either: 7.5 mM, 10 mM, 15 mlvi, 20 mM, or 30 mM. The remaining lens of each 
matched lens pair was placed in a corresponding medium except that either calpain 
inhibitor II or SJA6017 had been added. In all cases, the final concentration of each 
inhibitor corresponded to its IC50 value for calpain 2, which in the case of calpain 
inhibitor II was 500 nM (Maid et al., 1989) and in the case of SJA6017 was 0.8 pM 
(Fukiage et al., 1997). Each of these samples was then incubated at 25°C for 18 hours. 
After incubation, the lenses were extracted, excess medium gently removed using 
absorbent tissue, and the lenses photographed as described above. Lenses were then 
placed in sterile containers and frozen at -80°C until further rise. 
2.3.5 Atomic absorption spectroscopy. 
Lenses were allowed to come to room temperature and any visible moisture 
gently removed using absorbent tissue. The lenses were then weighed, individually 
placed in a microwave bomb containing 10 ml of concentrated nitric acid (70% w/v) 
and microwave digested at 180°C for 20 mm (CEM Mars X microwave). 
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The resulting samples were then evaporated to dryness in PTFE beakers using 
a heating plate and re-dissolved in 25 ml of nitric acid (5% w/v), which also contained 
lanthanum chloride (0.2 gm F') 
Figure 2.2 AT! Unicam Flame Atomic Absorption Spectrophotometer 
Figure 2.2 shows an interior view of a typical flame atomic absorption 
spectrophotometer, including: hollow cathode lamps (1), high temperature acetylene 
flame atomising calcium from sample (2), beaker containing test sample in solution 
(3), unit housing photo-multiplier diode (4) and console displaying 
spectrophotometric readings (5). 
The Ca2 content of the lens samples was then measured using atomic 
absorption spectroscopy (AT! Unicam Model 929, Figure 2.2). A set of Ca 2 
calibration standards were prepared, analysed in triplicate and used to produce a 
calibration curve for Ca 2 across the range 0 ppm to 10 ppm (Figure 2.5). Total lens 
Ca2 content was determined in triplicate and expressed as j.tmoles Ca 2 per gm wet 
lens weight. 
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2.3.6 Statistical analyses of porcine lens Ca 2 uptake data 
Mean Ca2 upthke by porcine lenses was plotted as a function of the extra-
lenticular Ca 2 concentration with error bars based on the standard deviation (SD). 
These plots were analysed to make comparisons between porcine lenses Ca 2 uptake 
in the presence and absence of: I) calpain inhibitor II, and 2) SJA6017, using a 
Regression in Groups model (Draper and Smith, 1998): 
y = 13o + (31x + 132'  + 1331*x + C 
where 13o, i3, 132, and f33 are the regression coefficients with (3o  the intercept for x, and 
131, 132, and 133  the coefficients for x, I and the interaction term I*x respectively; x 
represents porcine lens Ca 2 uptake, I is the dummy variable denoting group 
membership (I = 0 for Ca 2 uptake without inhibitor and I = 1 for Ca 2 uptake with 
inhibitor) and C is the error term. The Least Squares estimators for the regression 
coefficients, (32  and 133,  were analysed to establish statistically whether the curves 
representing porcine lenses Ca 2 uptake in the presence and absence of: 1) calpain 
inhibitor II, and 2) SJA6017, can be considered to be coincident. The results of these 
analyses are presented in Table 2.1. 
In this and Chapters 3, 4 and 5, the results are presented as original photographs, 
traces and as mean ± the standard deviation (SD). All data were analysed using 
MINI1TAB 13.1 statistical software. A 'p' value of <0.05 was taken as significant. 
2.4 RESULTS 
Here, the in vitro ability of Ca 2 to induce opacification in porcine lenses has 
been investigated. Preliminary experiments showed that when porcine lenses were 
incubated in LM supplemented with 30 mM Ca 2 ' for 12 hours, substantial lens 
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degradation occurred (Figure 2.3B and 2.3C). However, similar incubations for a 
duration of 18 hours at 25°C led to total opacification of the incubated lenses whilst 
preserving lens integrity (Figure 2.4B'). All future lens incubations were conducted 
under these conditions. 
Control lenses, which had been incubated in LM alone showed no evidence of 
opacification (Figure 2.4A). However, when incubated in LM, which was 
supplemented with increasing levels of Ca 2 (5.0 mM to 30 mlvi), lenses showed clear 
evidence of progressive opacification. LM supplemented with 10 mM Ca 2 marked 
the onset of significant opacity in these lenses whilst a 15 mlvi Ca 2 supplement, led to 
high levels of opacification, which occupied approximately 70% of lens volume 
(Figures 2.5C' and 2.5D'). Lenses incubated in LM, which had been supplemented 
with 30 mM Ca2  showed dense opacification, characteristic of advanced cataract 
formation.(Figure 2.4B). 
Figure 2.3 Examples of porcine lenses found unsuitable for investigation 
A 	 B 	 C 
Figure 23A shows a porcine lens exhibiting a pre-existing sectoral opacity. Such 
lenses were not considered for further investigation as clearly, pre-existing opacities 
will confound the extent of neo-cataract formation. Figures 23B and 23C show 
porcine lenses that have been incubated in LM, supplemented with 30 mlvi Ca 2t for 
12 hours and the early stages of disintegration can be seen. For these lenses, 
disintegration of the lens capsule in a small area causes the slow release of intra-
lenticular contents. As a result, the lens then loses its bi-convex spheroidal shape and 
normal consistency, ultimately becoming an opacified, irregular mass. All 
photography was performed as described in section 2.3.2. 
Atomic absorption spectroscopy was used to determine the total Ca 2 content 
of lenses that had been incubated in LM supplemented with increasing levels of Ca 2t 
Mean lens Ca2 uptake was plotted as a function of the extra-lenticular Ca 2 
concentration and it was found that a strong linear correlation (Table 2.1A and 2.1C) 
existed between porcine lens total Ca 2 content and levels of Ca 2 in the extra-
lenticular LM medium across the range 5 mM to 30 mM (Figures 2.6A and 2.613). 
The onset of opacification (10 mM extra-lenticular Ca 2 ) corresponded to a lens 
total Ca2 content of 5.8 j.tmoles Ca 2 (per gm wet lens weight). Increases in lens total 
Ca2 content correlated with progressively greater levels of lens opacification (Figure 
2.4 and 2.5), clearly showing a link between levels of porcine lens uptake of Ca 2 and 
degree of lens opacity. 
The previous experiments were repeated except that either calpain inhibitor II 
(final concentration 500 nM) or SJA6017 (final concentration 0.8 jiIvl) were included 
in the extra-lenticular medium. In each case, the Ca 2 uptake of lenses was plotted as a 
function of the extra-lenticular Ca 2 concentration and it can be seen from Figures 
2.6A and 2.6B that curves representing lens Ca 2 uptake in the presence of inhibitors 
appear to be coincident with curves representing lens Ca 2 uptake in the absence of - 
inhibitors. 
This was confirmed by analysis of these curves using a fitted Regression in 
Groups model (Draper and Smith, 1998), which showed that all p-values for the 132 
and (33 coefficients are not significant at the 5% level (Tables 2.IC and 2.ID). 
Analysis of the corresponding residuals confirmed that the distributional assumptions 
of Normality and homoscedasticity were met. These results indicate that neither 
calpain inhibitor II nor SJA6017 showed any significant effect on levels of lens total 
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Ca2 
 content across the range 5 mM to 30 mM (Figure 2.6A and 2.6B), showing that 
neither inhibited porcine lens uptake of Ca 2 
Figure 2.4 Porcine lenses exhibiting advanced opacification 
I' 
ff.7- 	
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Figure 2.4A shows a lens that has been incubated in LM alone and the background 
grid can be clearly seen, indicating that under these conditions, opacification was not 
induced. Figure 2.413' shows a lens that had been incubated in LM, supplemented 
with 30 mM Ca and the lens is densely opaque with the background grid completely 
obscured, typical of advanced cataract. Ai1}ëülViiëifliFfigure 24BWhtU
-
the lens was incubated in LM, supplemented with 30 mlvi Ca 2 and SJA6017 (final 
concentration 0.8 M), indicating that under conditions of high Ca 2t these levels of 
the calpain inhibitor have no detectable effect on levels of lens opacification. All 
photography was performed as described in section 2.3.2. 
ER 
Figure 2.5 The retardation of porcine lens opacification by SJA6017 
C , 
C 
Figure 2.5C' and 2.513' show porcine lenses that have been incubated in LM, 
supplemented with 10 mM and 15 mM Ca 2 , respectively. In Figure 2.5C', the onset 
of opacification is evidenced by a developing translucency, which cieates a significant 
blurring of the background grid lines. This effect has strongly progressed in Figure 
2.5D' where the background grid lines are largely obscured and the lens shows the 
development of several patches of Jocalised white opaque areas, which encompasses 
circa 70% of the lens volume. 
Figures 2.5C and 2.5D show porcine lenses that had been incubated in media 
-----------corresponding-thoseof2.5Cani2.5Dexcepuhat in both cases, SJA607 had been 
 
included in the medium (final concentration 0.8 lAM). In contrast to figure 2.5C', 
figure 2.5C shows that, although some optical distortion is present, the background 
grid lines can be more clearly seen through the lens than in Figure 2.5C. In Figure 
2.51), whilst opacification has clearly started in the lens with a diffuse obscuration of 
the black grid lines, this opacity occupies only circa 30% of the lens volume, 
representing a reduction of circa 40% of the opacity observed in Figure 2.513'. 
These results clearly show that SAJ6017 is able to retard porcine opacification under 
our experimental conditions. To highlight areas of opacification, higher levels of 
illumination were used when photographing these lenses, which were optimised in 
each case. All photography was performed as described in section 2.3.2. 
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Figure 2.6 Relationship between lens uptake of Ca 2 and extra-lenticular Ca2 
levels 
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Figure 2.6A shows Ca 2 uptake in porcine lenses, which were incubated in LM 
containing increasing levels of Ca 2 , either in the absence (,) or presence () of the 
calpain inhibitor SJA6017 (final concentration 0.8 pM). Figure 2.613 shows Ca 2 
uptake in porcine lenses that were treated identically except that incubations were 
conducted in the absence (,) or the presence (•) of calpain inhibitor II (final 
concentration 500 nM). It can be seen that in the absence of these inhibitors, there is a 
linear correlation between Ca 2 uptake levels and the concentration of Ca 2 in the 
extra-lenticular medium. It can also be seen that in both cases, the presence of calpain 
inhibitor in the extra-lenticular medium led to no significant change in this linear 
correlation, suggesting that neither inhibitor had any significant effect upon Ca 2 
uptake by porcine lenses. Experimental procedures were as described in section 2.3.5 
and each data point represents the mean of three experiments with error bars ± SD. 
Table 2.1 Statistical analyses of porcine lens Ca 2 uptake data 
Correlation Coefficient P-value 
Calpain Inhibitor H present 0.964 <0.0005 
Calpain Inhibitor II absent 0.985 <0.0005 
Table 2. 1A shows the Pearson Product-Moment correlation coefficient for Ca 2 
uptake by porcine lenses with and without calpain inhibitor II present, against extra-
lenticular Ca2 
 concentrations with P-values for test of significance. 
Regression Coefficient Least Squares Estimate P-Value 
13o -0.0445 0.908 
0.56882 <0.0005 
132 0.3301 0.547 
133 -0.04641 0.190 
Table 2.113 shows Regression Coefficients for Regression in Groups fit of Ca 2 uptake 
byporcine lenses with and without calpain inhibitor II present, against extra-lenticular 
Ca + concentrations (Adjusted Coefficient of Determination=0.96; Anderson-Darling 
statistic for Normality of residuals, AD=0.391, P=0.365). 
- 
Correlation Coefficient P-value 
SJA6017 present 0.983 <0.0005 
SJA6017 absent 	 1 0.975 <0.0005 
- 
uptake by porcine lenses with and without SJA6017 present, against extra-lenticular 
Ca2 
 concentrations with P-values for test of significance. 
Regression Coefficient Least Squares Estimate P-Value 
- -0.0245 0.948 
01 0.53853 <0.0005 
132 0.1485 0.780 
I 	 13 3 -0.06559 	 I 0.590 
Table 21D shows Regression Coefficients for Regression in Groups fit of Ca 2 uptake 
by porcine lenses with and without SJA60I7 present, against extra-lenticular Ca 2 
concentrations (Adjusted Coefficient of Determination=0.96; Anderson-Darling 
statistic for Normality of residuals, AD=0.391, P=0.365). 
EEO 
The effect of calpain inhibitor II and SJA6017 on the C a2tmedi ated 
opacification of porcine lenses was tested. These lenses were incubated in LM that 
had been supplemented with increasing levels of Ca 2 (5.0 mM to 30 mJvI) and either 
calpain inhibitor II (final concentration 500 nM) or SJA6017 (final concentration 0.8 
iiM). At extra-lenticujar Ca 2 concentrations of 10 mM and 15 mM, the presence of 
SJA6017 (Figures 2.5C and 2.5D) led to reductions in levels of lens opacity when 
compared to those in lenses that had been incubated in corresponding media but 
lacking the inhibitor (Figures 2.5C' and 2.5D'). At 15 nilvl Ca 2t this decrease in lens 
opacity was of the order of 40% of lens cell volume, showing that SJA60I7 was able 
to retard the onset of porcine opcification (Figure 2.5D). At extra-lenticular Ca 2 
concentrations of 30 mM, the levels of SJA6017 used in these experiments showed no 
significant effect on the advanced state of opacification observed in porcine lenses 
(Figures 2.413 and 2.413'). In contrast to SJA6017, calpain inhibitor II showed no 
significant ability to retard Ca2tinduced porcine lens opacification under the 
experimental conditions used here (Figure 2.7). 
2.5DISCUSSION 
In lenses which had been incubated in LM alone, lens total Ca 2 content was 
found to be 0.38 jtmoles Ca2 (gm wet lens weight) - '. Comparable values for total 
Ca2 
 in the normal lenses of other mammalian species were reported by Shi et al., 
(1994), which varied between 0.11 and 0.6 gmoles Ca 2 (gm wet lens weight)'. As 
LM was increasingly supplemented with Ca 2t a strong, almost linear response was 
shown by levels of porcine lens total Ca 2 content, implying progressively increased 
Ca2 
 uptake by these lenses (Figure 2.6). Moreover, this Ca 2 uptake correlated with 
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Figure 2.7 The effect of calpain inhibitor 11 on porcine lens opacification 
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Figure 2.7A shows a porcine lens that has been incubated in LM alone and the 
background grid can be clearly seen, indicating that under these conditions, 
opacification was not induced. Figure 2.713' shows a porcine lens that had been 
incubated in LM, which was supplemented with 15 mM Ca 2 . Similarly to figure 
2.7C', the background grid lines are largely obscured with the lens showing the 
development of opacification, which encompasses circa 70% of the lens volume. 
Figure 2.713 shows a porcine lens that had been incubated in a medium corresponding 
to that of 2.713' except that calpain inhibitor II (final concentration 500 nM) had been 
included in the medium. The levels of opacity shown by this lens shows no 
appreciable difference to that shown in figure 2.713' indicating that calpain inhibitor II 
was unable to retard opacification under these conditions. The lenses shown in figures 
2.7C' and 2.7C were incubated in media that corresponded to those of figures 2.713' 
and 2.713, respectively, except that 30 mM Ca 2 was included in these media. Again, it 
can be seen that the presence of calpain inhibitor II led to no apparent reductions in 
- lens 
opacity, typical of advanced cataract. All photography was performed as described in 
section 2.3.2. 
increasing levels of lens opacification (Figures 2.4 and 2.5) and in combination, these 
results suggest that the activation of porcine lens calpains could be involved in this 
opacification. To investigate this suggestion further, the previous experiments were 
repeated except that either SJA60I7 or calpain inhibitor II were included in the extra-
lenticular medium. It can be seen from Figure 2.7 that calpain inhibitor II showed no 
apparent ability to retard porcine opacification. However, previous studies have 
shown this compound able to retard the opacification associated with cataractogenesis 
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(Tamada et al., 2001; Mathur et al., 2000; Fukiage et al., 1998; Fukiage et al., 1997) 
and a possible explanation for the results found here is that calpain inhibitor II shows 
low permeability to porcine lens cell membranes, thus inhibiting uptake of the 
inhibitor. In contrast, it can be seen from Figure 2.4 that whilst the presence of 
SJA6017 had no significant effect on the development of advanced lens opacification, 
it significantly affected earlier stages of lens opacification (Figure 2.5). This effect 
would not appear to be due to SJA6017 restricting the uptake of Ca 2 by porcine lens 
as the presence of the inhibitor had no significant effect on the ability of extra-
lenticular Ca 2 to induce changes in the total Ca 2 of porcine lenses (Figure 2.6A). In 
combination, these results strongly suggest that the ability of SJA60I7 to retard the 
observed porcine opacification is due to its ability to inhibit calpains, which have been 
activated in response to elevated levels of lens Ca 2t 
The levels of opacification seen in porcine lenses in the presence of 30 mM 
extra-lenticular Ca 2 (Figure 2.413') corresponds to that observed in advanced cortical 
cataract (Biswas et al., 2004). The total Ca 2 content of these lenses was of the order 
of 16.0 jimoles Ca2 (gm wet lens weight)', which corresponds to a value of 
rifthIy thiiithoè a2 g1 itèi5' iiid ddthaièTii6 the vàlñèThf2V --
millimoles Ca2 (Kg lens water) - ' recently reported for advanced age-related cortical 
cataract in human lenses (Tang et al., 2003b). This comparability of Ca 2 levels at 
similar stages of cataract, suggests that there may be similarities in the levels of 
calpain activation shown by human and porcine lenses in the disorder. Current 
understanding is that calpain 2 is probably the only major calpain activated in human 
cataractogenesis (section 1.5.3) and it is interesting to note that, at the onset of porcine 
opacification observed in the present study (10 mM extra-lenticular Ca 2 ), the total 
lens Ca2 was of the order of 5.5 jimoles Ca 2 (gm wet lens weight)- ', which 
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corresponds to a lens water Ca 2 concentration of approximately 8.2 mM. It is well 
established that millimolar levels of the ion lead to the direct activation of calpain 2, 
whose normal in vitro activity is tightly regulated by a variety of factors (section 
1.5.4; Goll et al., 2003). Moreover, it can be seen from Figure 2.5 that SJA6017 
significantly inhibited the onset of porcine opacification and SJA6017 is known to 
strongiy inhibit calpain 2 activity (Fukiage et al., 1997). 
Taking these results overall, it would seem that they provide a basis for further 
investigations. The porcine lens may be a useful model for investigating some aspects 
of human cataractogesesis. SJA6017 is clearly taken up by porcine lenses and shows 
considerable efficacy in reducing their opacification. It has previously been suggested 
that calpain inhibitors could be developed as anti-cataract agents for use in cases 
where surgery is not an option, and in the treatment of diabetic cataract as a 
complement to conventional diabetes therapy (Biswas et aL, 2003). SJA6017, or its 
derivatives, may be suitable for development in such capacities. Indeed, supporting 
this suggestion, analogues of SJA1067 have recently been shown to be efficacious in 
inhibiting nuclear cataract in a rat lens culture model (Nakamura et al., 2003). 
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CHAPTER 3 
A theoretical investigation into the potential of 
calpain 2, domain V, to form lipid interactive 
secondary structure 
Biswas, S., Harris, F., Daman, 0 A., Wallace, J., Phoenix, D. A. (2001) A theoretical 
investigation into the role of amphiphliic a-helical structure in the lipid interactions 
of m-calpain. Abstracts of the Association for Research in Vision and Opthalmology, 
Investigative Opthalmology and Visual Science 42, p  5877, No 4710-13729; Daman, 
0. A., Biswas, S., Harris, F., Wallace, J. and Phoenix, D. A. (2001) A theoretical 
163. 
54 
3.1 ABSTRACT 
Calpain 2 is a calcium-dependent heterodimer whose activation appears to be 
modulated by membrane interaction involving a segment, G17TATvIIRILGQ, in domain 
V of the enzyme's smaller subunit. Here, sequence analysis of calpain 2 from a 
number of mammalian species showed domain V from each to possess a segment, 
centred on the TAIMIRIL sequence, with the potential to form a lipid interactive a-
helix. These a-helical segments showed high levels of homology between species and 
comparable DWIH values, circa 7.0, indicating high membrane interactive potentials. 
Additionally, these a-helices were found to possess comparable hydrophobic 
moments (c PH>) of the order of 0.5, which identified them as candidate oblique 
orientated a-helices. Consistent with this result, hydropathy plot analysis showed each 
a-helix to possess a significant N -* C hydrophobicity gradient whilst graphical 
analysis demonstrated that each a-helix possessed strong structural similarities to the 
known oblique orientated a-helix of the influenza HA2 peptide. Based on these 
-_  in the membrane activation of calpain 2 may 
be oblique angled penetration of the membrane by a-helical structure in domain V of 
the enzyme. 
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3.2 INTRODUCTION 
As described in chapter 1 the membrane activation model for calpain 2 is that 
most generally accepted. Membrane interaction is a preliminary event in this model 
and previous studies have shown that a C-terminal segment, G17TAMTRILGG, in 
domain V of the enzymes smaller subunit is required for these interactions (Crawford 
et al., 1990). A previous sequence analysis of domain V from porcine calpain 2 
revealed no potential for either amphiphilic (3-sheet or amphiphilic u-helix formation 
(Crawford et al., 1996), the major elements of membrane interactive secondary 
structure found in proteins (Phoenix et al., 2002). Here, the sequence of domain V 
from calpain 2 is analysed using several recently developed techniques for the 
detection of protein segments with membrane interactive potential. The primary 
structures of domain V from porcine, human, bovine and rabbit calpain 2 (table 2.1.) 
are analysed using the DWIH (depth weighted insertion hydrophobicity) algorithm of 
Roberts et al., (1997). This algorithm identifies protein segments with the potential to 
form membrane interactive u-helices and provides a novel quantitative measure of 
this potential. These calpain 2 sequences are also analysed according to &xtendè 
hydrophobic moment plot methodology (Harris et al., 2000; Eisenberg et al., 1984), 
which identifies protein segments with the potential to form oblique orientated a-
helices. These a-helices possess highly specialised structure / function relationships 
and are characterised by the possession of hydrophobicity gradients, which facilitate 
membrane penetration at a shallow angle (Brasseur, 2000). Supported by graphical 
analysis (Hennig, 1999) and hydropathy plot analysis (Kyte and Doolittle, 1982), the 
results obtained from these sequence analyses showed that each calpain 2 examined 
possesses a domain V segment, centred on the TAIvIRIL sequence, with the potential 
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to form a lipid interactive oblique orientated a-helix. It is predicted that such structure 
may play a role in the membrane activation of calpain 2. 
3.3 EXPERIMENTAL 
The sequence of the HA2 influenza peptide, and those of domain V from 
human, bovine, porcine and rabbit calpain 2 (tables 3.1 and 3.2.) were obtained from 
the "SWISSPROT" data bank, (http://ca.expasy.orgJsrod , accessed 13.12.03) and 
tested for homology using the Match-box Web Server 1.3 facility for protein sequence 
alignment (http://www.sciences.fundp.ac.befbiologie/bms/matchbox 
 submit.shtm), 
accessed, 13.12.03). The ability of these calpain 2 domainsto form lipid interactive a-
helical structure was then investigated using the depth-weighted inserted 
hydrophobicity (DWIIT) algorithm of Roberts et al., (1997) and the extended 
hydrophobic moment plot analysis of Harris et al., (2000). 
3.3.1 DWIH analysis 
The DWIH algorithm provides a measure of membrane interactive potential 
by maximising the sequestration of hydrophobic residues within a hydrophobic 
compartment. The window size is not fixed but optimised to identify the maximum 
window size, which could potentially interact with the membrane. A statistical 
significance for the measure is obtained by Monte-Carlo techniques, which take into 
account the significance of the amino acid residues present (uniform test) and the 
significance of the arrangements of the amino acid residues around the a-helix 
(random test). The DWIH algorithm was used to analyse the calpain 2 domains shown 
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in table 3.1 for the ability to form lipid interactive a-helical structure (tables 3.2 and 
3.3). 
3.3.2 Extended hydrophobic moment plot methodology 
This methodology first uses hydrophobic moment analysis (Eisenberg et al., 
1982a) to identify putative a-helical sequences and to quantify their amphiphilicity. 
Essentially, the hydrophobic moment measures the structured partitioning of 
hydrophilic and hydrophobic residues in a regular repeat structure of period 0 and 
hence can provide a measure of a-helical amphiphilicity (Eisenberg et al., 1984). To 
determine the hydrophobic moment, the hydrophobicities of consecutive residues in a 
putative a-helical sequence are treated as vectors with positive values implying that a 
residue is hydrophobic. A vector with magnitude proportional to the hydrophobicity 
of amino acid, k, is drawn from the a-helical long axis towards the central a-carbon 
of the amino acid residue. The hydrophobic moment is defined by: 
g(0) = { 
	
Hksin(kSj] 2 + 
	
Hkcos(kO)] 2 
 } 
where t(0) is the hydrophobic moment of a sequence of length 1 residues. Hk is the 
hydrophobicity of residue k, and is usually quantified according to the normalised 
consensus .hydrophobicity scale of Eisenberg et al., (1982b). The usual analytical 
approach is to consider a window, with a length of eleven amino acid residues, 
progressing along the amino acid sequence and for each window, the associated 
hydrophobic moment at 1000 
 is calculated. Windows with maximl values of j4100 °) 
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are taken as the most likely candidates for amphiphilic a-helix formation. The 
amphiphilicity of an a-helix thus identified is given by the more usual form of the 
hydrophobic moment, <PH>,  which is defined by pi(100°) / 11. For the calpain 2 
domains shown in Table3.2. <p11 > and the corresponding mean hydrophobicity,c H 
>, were computed and these results are presented in Table 3.3. With these data, 
extended hydrophobic moment plot methodology then attempts to classify putative a-
helical sequences as either globular, transmembrane, surface active or oblique 
orientated. Accordingly, the values of c PH> and < H > computed for the windows 
identified in Table 3.2 were used as coordinate pairs to represent their parent a-
helices as data points (Figure 3.1) on the extended form of the hydrophobic moment 
plot diagram (Harris a al., 2000; Eisenberg a al., 1984). For comparative purposes, 
the HA2 peptide, which is known to form a lipid interactive oblique orientated a-helix 
(Brasseur, 2000), was similarly analysed (Tables 3.2 and 3.3) and plotted (Figure 3.1). 
3.3.3 Hydropathy plot analysis and graphical analysis 
Wingen/Winpep software from Google (Hennig, 1999) was used to perform 
hydropathy plot analysis on the m-calpain common segment, GTAIvIIRILGGVI (Table 
3.2), using the hydrophobicity scale of (Kyte and Doolittle, 1982) and a seven-residue 
window (Figure 3.2). This software was also used to model this latter sequence and 
that of the HA2 peptide as two-dimensional axial projections, taken perpendicular to 
the helical long axis and assuming an amino acid periodicity of 100° (Figure 3.3). 
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3.4 RESULTS AND DISCUSSION 
It has been suggested that the enzymatic activity of calpain 2 may be 
modulated by membrane interaction involving the small subunit of the protein 
(section 1.5.3.1). Experimental results obtained for porcine calpain 2 have shown that 
domain V of the protein's small subunit possesses a C-terminal segment with the 
sequence TAMRIL, which is required for calpain 2 - lipid interaction (Arthur and 
Crawford, 1996). Here, theoretical analyses were used to investigate the possibility 
that this lipid interaction may involve amphiphilic a-helical secondary structure. The 
primary structure of domain V of calpain 2 was derived for a number of mammalian 
species and analysis of these sequences showed that they possessed high levels of 
homology (> 90%) with each sequence possessing a C-terminal TAIvIRIL segment 
corresponding to that found in porcine calpain 2 (Table 3.1). These primary structures 
were then analysed according to the DWIH methodology of Roberts et al., (1997) and 
for each sequence analysed, a putative a-helical region was identified (Table 3.2). 
These a-helical regions showed high levels of homology and possessed the common 
sequence GTAMIRILGGVI, which can be seen from Table 3.2 to include the 
TAMRIL segment identified by Crawford et al., (1996). Based on these results, we 
suggest that the TAIvIIRIL segment may contribute to an amphiphilic a-helical region, 
which is present in domain V of each calpain 2 analysed. This suggestion is reinforced 
by the results of a further analysis of the domain V primary sequences shown in table 
3.2. The hydrophobic moment methodology of Eisenberg et al., (1982a) identified 
putative lipid interactive sequences in each case, which showed 100% overlap with 
those identified by DWJIH analysis. 
Ell 
Table 3.1 Sequence homology of domain V from various mammalian m-calpains 
m-calpain Domain V sequence 
Human MFLVNSFLKGGGGGGGGGGGLGGGLGNVLGGLISGA 
GGGGGGGGGGGGGGGGGGGGTAMRTILGGVI 
Rabbit MFLVNSFLKGGGGGGGGGGLGGGLGNVLGGLISGAG 
GGGGGGGGGGGGGA000GTAMRILGGVI 
Porcine MFLVNSFLK0000GGGGOGGLGGGLGNVLGGLISGA 
GG0000GGGGGGGGGGGGTAMRILGGVISAI 
Bovine MFLVNSFLKGGGGGGGGGGGLGGGLGNVLGGLISGA 
GGG000GGGGG0000GGGTAMRILGGVISAI 
Table 3.1 shows the primary sequence of domain V from calpain 2 of various 
mammalian species. Multiple sequence alignment, as described in section 3.3, showed 
these domains to possess 80% homology. 
Table 3.2 a-helical regions identified in the primary structures of calpains 
Protein or peptide Domain V sequence 
Domain V from human calpain 2 000GTAMRILGGVI 
66maV6oñbhitãljiãiW2 GGGGTAcM14ThGGVI-- 
Domain V from porcine calpain 12 GQGGTAMIRILGGVISAI 
Domain V from bovine calpain 2 GGGGTAMRILGGVISAI 
Influenza virus, fusion peptide HA2 GLFGAL&GFIENGWEGMIDG 
Table 3.2 shows putative a-helical regions, which were identified in the primary 
structure of various calpain 2 domain V species, and the HA2 viral fusion peptide. 
These sequences were identified according to either the hydrophobic moment 
methodology of Eisenberg et al., (1982a) (shown in bold) or the DWITI methodology 
of Roberts et al., (1997) (shown underlined), all as described in sections 3.3.1 and 
3.3.2. 
r.i 
Table 3.3 Hydrophobic moment and DWIH parameters for a-helical regions 
identified in calpains 
Protein Parameters derived 
from hydrophobic 
moment analysis  
Parameters derived from DWIH 
analysis 
cu,,> <H> DWIH Uniform 
significance 
Random 
significance 
Human calpain 2 0.46 0.47 6.16 1.2 0.5 
Rabbit calpain 2 0.46 0.47 6.16 1.2 0.5 
Porcine calpain 2 0.57 0.54 7.91 0.3 <0.001 
Bovine calpain 2 0.57 0.54 7.91 0.3 <0.001 
Influenza HA2 0.23 0.48 - - - 
For the putative a-helical regions shown in table 3.2 table 3.3 shows values of < H > 
and < PH >, which were computed according to the hydrophobic moment 
methodology of Eisenberg et al., (1982a) and, DWIH values and associated 
parameters, which were computed according to the methodolbgy of Roberts a' cii., 
(1997), all as described in sections 3.3.1 and 3.3.2. 
For each putative a-helical region identified by hydrophobic moment analysis, 
the values of <PH> and < H > were computed (Table 3.3) and these values then used 
to plot data points (Figure 3.1) on the extended hydrophobic moment plot diagram 
(Harris et cii., 2000; Eisenberg a' cii., 1984). It can be seen from Figure 3.1 that these 
data points lie in the area delineating candidate oblique orientated a-helices, proximal 
to that of the HA2 peptide, which is known to form such an a-helix. These 
observations suggest that the calpain 2 segments analysed may form oblique 
orientated a-helices. This suggestion is reinforced by the results of hydropathy plot 
analysis of these sequences, (Figure 3.2), which showed that there was a progressive 
increase in hydrophobicity in moving from the N-terminus to the C-terminus (Figure 
3.2), suggesting the ability to form an a-helix with an asymmetric distribution of 
hydrophobicty along the a-helical axis. 
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Figure 3.1. Hydrophobic moment plot analysis of protein segments 
Man hirophóbicity 
Figure 3.1 shows the conventional hydrophobic moment plot diagram of Eisenberg et 
cii., (1984) with an overlaid grey region delineating candidate oblique orientated a-
helices (Harris et al., 2000). The sequences shown in table 3.2 were plotted on the 
diagram according to their <PH> and corresponding c H0 > values (table 3.3), all as 
described in section 3.3.2. The data point representing the calpain 2, domain V 
segment, GTAMIRILGGVI (1), can be seen to lie in the grey region, proximal to that 
represinting the HA2 peptide (2), indicating that the segment may be a candidate for 
oblique orientated a-helix formation. 
Figure 3.2. Hydropathy plot analysis of protein segments. 
:0 
Residue number 
Figure 3.2. shows an hyciropathy plot analysis of the calpain 2, domain V segment, 
GTAMRILGGVI, performed using a seven residue window and the software of 
Hennig (1999), all as described in section 3.3.3. It can be seen that hydrophobicty 
progressively increases along the length of the segment with a maximal value centred 
on the C-terminal glycine, residue 8. 
13] 
Similar asymmetric distributions of hydrophobicity, or hydrophobicity gradients, are 
found in the a-helices of viral fusion peptides such as HA2, and these ct-helices 
possess highly specialised structure / function relationships; their hydrophobicity 
gradients facilitating membrane penetration at a shallow angle and the promotion of 
membrane fusion (Brasseur, 2000). It has been established that both the nature and the 
spatial organisation of the amino acid residues forming oblique orientated u-helices is 
important for their biological activity (Nievea and Agirre, 2003; Fujii, 1999; Decout 
et cii., 1999). The DWIH measure of the predicted u-helical regions (Table 3.2) have 
been computed and the results show that both the uniform and random significance of 
these measures is cc 5%, indicating that both the nature and the order of the amino 
acid residues forming these u-helices is highly significant. To investigate this 
observation further, the sequence common to the predicted domain V a-helical 
regions, GTAMRILGGVI, and that of the HA2 peptide (Table 3.2), were taken and 
represented as a two dimensional projections (Figure 3.3). It can be seen from figure 
3.3 that both sequences exhibit structural similarities with each possessing a narrow 
hydrophilic face, whh is rich in glycine residues and a wide hydrophobic face, 
which is rich in bulky amino acid residues. Moreover, it can be seen for the 
GTAMIRILGGVI projection that the bulky residues, leucine and isoleucine are 
preponderant in the C-terminal region of the a-helix. This localisation of strongly 
hydrophobic amino acid residues is structurally consistent with the higher levels of 
hydrophobicity predicted for the C-terminal region of the segment (Figure 3.2) and 
possession of an hydrophobicity gradient (Phoenix et al., 2002; Brasseur, 2000). 
Figure 3.3. Two-dimensional axial projections of protein sequences 
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Figure 3.3. shows the primary structures of: (A) the influenza peptide, HA2, a known 
oblique orientated a-helix former and (B) the putative oblique orientated a-helix 
forming segment identified in calpain 2, domain V (table 3.2), represented as two-
dimensional axial projections using the software of Hennig, (1999), all as described in 
section 3.3.3. Annotated numbers represent the relative locations of amino acid 
residues within protein primary structure and hydrophobic residues are circled. It can 
be seen that each u-helix possesses a glycine rich polar face and a wide hydrophobic 
face rich in bulky amino acid residues. In the case of the GTAMRILGGVI segment 
these residues, isoleucine (6) and leucine (7 and 11) can be seen to be localised in the 
C-terminal region of the a-helix. 
and others of this a-helical class have shown that the 
positional preferences of glycine residues are core to the function of these a-helices 
(Fujii, 1999). It has been suggested that the presence of glycine residues within these 
a-helical arrangements is required to maintain the balance between hydrophilicity and 
amphiphilicity needed for membrane interaction (Harris et al., 2000) and we speculate 
that this could be the case for our predicted a-helical regions. 
In conclusion, it is suggested that the lipid interactions of each calpain 2 
analysed involves an amphiphilic a-helical region in domain V, which includes the 
TAIvIIRIL segment identified by Arthur and Crawford, (1996). These a-helical regions 
show a number of structural resemblances to proteins and peptides, which associate 
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with lipid / membranes via oblique orientated a-helices. Based on these results, it is 
suggested that an early stage in the membrane activation model proposed for calpain 2 
may be oblique angled penetration of the membrane by a-helical structure in domain 
V of the enzyme. Clearly, these results form a basis for future investigations into the 
role of lipid / membranes in the activation of calpain 2 and such investigations are 
undertaken in chapters 4 and 5. 
CHAPTER 4 
Biophysical investigation into the potential of domain 
V, calpain 2, to form lipid interactive secondary 
structure 
Phoenix, D. A., Dennison, S., Harris, F., Hau(3, T., Dante, S., Brandenburg, K. and 
Biswas, S (2003) Investigations into the membrane interactions of m-calpain, an 
enzyme implicated in diabetic cataractogenesis. 4 th International Symposium on 
Diabetes Mellitus and its Complications: From Molecular Biology to Clinical 
Medicine. Preston. p18; Biswas, S., Daman, A., Harris, F. and Phoenix, D A. (2001) 
A theoretical investigation into the lipid interaction of m-calpain. Proceedings of the 
4th European Symposium of the Protein Society, Protein Science 10, (suppl 1), p  149, 
No. 367; Biswas, S., Harris, F. and Phoenix, D. A. (2001) The lipid interactions of m-
calpain. Abstracts of the Biochemical. Society, 675th meeting, p39, No 51. 
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4.1 ABSTRACT 
In chapter 3 it was predicted that a lipid interactive oblique orientated a-helix, 
formed by a GTAMIRILGGVJ segment in domain V of calpain 2 may feature in the 
membrane activation of the enzyme. Here, FTIR conformational analysis shows a 
peptide homologue of this segment, VP!, to be predominantly f3-sheet in free solution 
but to adopt a-helical structure in the presence of DMIPC (20%) and DMIPS (65%). 
The peptide interacted strongly with monolayers formed from either of these lipids (A 
SP = 5.0 
- 5.5 mN mS') at surface pressures mimetic of naturally occurring membranes 
( 30 mN m') but by apparently different mechanisms in each case. VP1 interacted 
primarily with the headgroup region of DIVIPC monolayers but was able to penetrate 
the membrane core region of DMPS monolayers. Additionally, the presence of ionic 
agents reduced the ability of VP1 to penetrate DMIPS monolayers by approximately 
50%. The peptide also showed strong haemolytic ability (half-maximal haemolysis = 
1.45 mM) and based on these combined results, it is suggested that anionic lipid 
facilitates haemolysis and membrane penetration of VP1 via mechanisms that are 
 
- 
 
---------- ---consistent- with-its-adoption_of_obliqueorientated_ahelical_structure._mese_results 
strongly support the predicted use of such structure by domain V of calpain 2 in the 
membrane activation model of the enzyme (chapter 3). 
4.2 INTRODUCTION 
A wide variety of biophysical systems have been developed to study the 
interactions of proteins / peptides with membranes and these may be generally 
subdivided into those that use model membranes and those that use naturally 
occurring membranes. The most commonly used systems based on naturally occurring 
membranes are whole cell lytic systems, which are cells possessing an internal 
biomarker that can be quantitatively determined when externalised, thus providing a 
measure of protein mediated membrane lysis. To study the interactions of proteins 
with prokaryotic membranes, bacterial cells have been genetically engineered to 
produce enzymes or proteins that are chosen for their ability to serve as biomarkers of 
bacteriolysis (Harris et al., 2003). However, to study the interactions of proteins / 
peptides with eukaryotic membranes, the most widely used approach is haemolytic 
analysis in which proteins under study are incubated with erythrocytes. The 
haemoglobin of these cells acts as a naturally occurring biomarker of protein-
mediated erythrocyte lysis and is readily quantified spectrophotometrically when 
released from the cell (Brandenberg et al., 2002; Harris and Phoenix, 1997). 
Liposomes are frequently used as model membranes and provide a good 
physical mimic of the whole-cell membrane systems found in vivo. Such lipid bodies 
are often used to provide a lipid / water interface, mimicking the amphiphilic 
environment of a membrane surface, when studying the conformational behaviour of 
proteins in the presence of membranes. The other major model used to mimic 
naturally occurring membranes is the monolayer system, which possesses a number of 
advantages over other membrane models. Monolayers allow chosen parameters to be 
widely varied, including: the nature of the lipid molecules forming the monolayer, the 
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composition of the subphase, and a variety of incidental factors such as pH and 
temperature. This choice permits a variety of in vivo situations to be mimicked and 
moreover, monolayers generally possess stability and well-established planar 
geometry where the lipid molecules have a specific orientation, assisting the 
interpretation of lipid / monolayer interactions (Maget-Dana, 1999), However, 
perhaps the major advantage of monolayer use in membrane studies is that their 
surface pressure can be adjusted to choice and an initial surface pressure of 30 mN 
M' is known to be mimetic of naturally occurring membranes (Demel, 1974). Thus, 
with an appropriate choice of lipid(s), a variety of specific in vivo membrane 
situations can be mimicked and used to investigate differing physiological functions 
of membrane interactive proteins and peptides. 
In chapter 3, theoretical analyses predicted that domain V of calpain 2 
possessed a segment, GTAMIRILGGVI, with the potential to form a lipid interactive 
oblique orientated a-helix, which may feature in the membrane activation model of 
the enzyme. Here, FTIIR spectroscopy is used to study the conformational behaviour 
of a peptide homologue of this segment, VP1, in the presence of zwitterionic and 
anionic liposornes. Langmuir-Blodgett troughs were used to investigate the ábilit df 
the peptide to interact with monolayers formed from these respective lipid types 
whilst the interactions of VP! with naturally occurring membranes are studied using 
haemolytic analysis. 
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4.3 MATERIALS AND METHODS 
4.3.1 Reagents 
The peptide VP1 with sequence GTAMRILGGVI was supplied by PEPSYN, 
University of Liverpool, UK, produced by solid-state synthesis and purified by HPLC 
to a purity of greater than 99%. The peptide was stored as a stock solution (10 mM) in 
10% (v/v) ethanol at 4°C. Human erythrocytes were supplied by the Royal Preston 
Hospital, UK. Dimyristoyl phosphatidylcholine (DMIPC), dimyristoyl 
phosphatidylserine (DMPS) and all solvents, which were of spectroscopic grade, were 
purchased from Sigma (UK). 
4.3.2 Preparation of phospholipid small unilamellar vesicles 
Small unilamellar vesicles (SUV's) were prepared according to Keller et al., 
(1992). Essentially, lipid / chloroform mixtures were dried with nitrogen gas and 
- -------- hyt&wkqcpN-[2-Hydroxyethy1piperazine-N'-[2-ethanesulphonic acid],
(HEPES) at pH 7.5 to give final phospholipid concentrations of 50 mM. The resulting 
cloudy suspensions were sonicated at 4°C with a Soniprep ISO sonicator (amplitude 
10 milli-decibels) until clear suspensions resulted (30 cycles of 30 seconds), which 
were then centrifuged (15 mm, 3000 g, 4°C). 
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4.3.3 FTIR conformational analyses of VP1 
To give a final peptide concentration of 1 mIvi, VP1 was solubilised in 50 mM 
aqueous HEPES (pH 7.5) or suspensions of SUV's, which were formed from either: 
DMPS, DMPC or DMPE, prepared as described above. Samples of solubilised 
peptide were spread on a CaF2 crystal, and the free excess water was evaporated at 
room temperature. The single band components of the VP1 amide I vibrational band 
(predominantly Cr0 stretch) was monitored using an FTIR '5-DX' spectrometer 
(Nicolet Thstruments, Madison, WI, USA) and for each sample, absorbance spectra 
produced (figure 4.1). These spectra were analysed and for those with strong 
absorption bands, the evaluation of the band parameters (peak position, band width 
and intensity) was performed with the original spectra, if necessary after the 
subtraction of strong water bands. In the case of spectra with weak absorption bands, 
resolution enhancement techniques such as Fourier seif-deconvolution (Kauppinen et 
al., 1981) were applied after baseline subtraction with the parameters: bandwidth, 22-
28 cm, resolution enhancement factor, 1.2-1.4 and Gauss / Lorentz ratio of 0.55. In 
the 6ase of ovël iiiiIbãñd Uñëfifting wasa iliediLihgrhibdifioU versinOf 
the CUIRFIT procedure written by D. Moffat (National Research Council, Ottowa, 
Canada). An estimation of the number of band components was obtained from 
deconvolution of the spectra, curve fitting was then applied within the original spectra 
after the subtraction of baselines resulting from neighbouring bands. Similar to the 
deconvolution technique, the bandshapes of the single components are superpositions 
of Gaussian and Lorentzian bandshapes. Best fits were obtained by assuming a Gauss 
fraction of 0.55 - 0.6. The CURFIT procedure measures the peak areas of single band 
components and after statistical evaluation, determines the relative percentages of 
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primary structure involved in secondary structure formation. For VP1, relative levels 
of a-helical structure (1650 cm 4 - 1655 cm) and f3-shet structures (1625 cm 1 
1640 cm') were computed and are shown in Table 4.1. 
4.3.4 Monolayer studies on VP1 
All monolayer equipment was supplied by NIIvIA (UK). Surface tension was 
monitiored by the Wilhelmy plate method using a microbalance (Demel, 1974). 
Studies were conducted using a 5 x 15 cm Teflon trough containing 80 ml of buffer 
subphase (10 mM Tris buffer, pH 7.5). 
Figure 4.1 Langmuir-Blodgett trough for monolayer studies 
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The trough was equipped with moveable barriers, which responded to the 
microbalance and could be adjusted to maintain monolayers at either constant surface 
pressure or constant surface area. Monolayers were formed by spreading pure 
phcispholipids (10 mlvI) in chloroform, compressed to give a surface pressure of 30 
mN ni' and then maintained at constant area. Stock VP1 was added to the subphase 
via a reservoir extending into the subphase, which was contniuously stirred by a 
magnetic bar and VP1 - monolayer interactions were recorded as changes in 
monolayer surface pressure (Figure 4.2) 
43.5 Haemolytic assay of YP1 
Haemolytic assay was conducted according to (Harris and Phoenix, 1997). 
Essentially, packed red blood cells were washed three times in Tris Buffered Sucrose 
(TBS; 0.25M sucrose, 10mM Tris, pH 7.5) and resuspended in the same medium to 
give an initial blood cell concentration of approximately 0.05 gm%(w/v). For the 
haemolytic assay, this concentration was adjusted such that incubation with 0.1% 
- (vlv) TritonX-100 for 1 hour produced a supernatant with A 416 = 1.0 and this was 
taken as 100% haemolysis. Varying amounts of VP1 were solubilised in aliquots (1 
ml) of blood cells at assay cohcentration and the resulting mixtures incubated at room 
temperature with gentle shaking. After 1 hour the suspensions were centrifuged at low 
speed (1500g, 15 mm, 25°C) and the A 416 of the supernatants determined. In all cases, 
levels of haemolysis were determined as the % haemolysis relative to that of Triton-
X100 and the results recorded (Figure 4.3). The addition of buffer instead of peptide 
gave a basal lysis of less than 1 % in all cases. 
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4.4 RESULTS AND DISCUSSION 
Theoretical analyses have predicted that a lipid interactive oblique orientated 
a-helix, formed by a GTAMIRILGGVI segment in domain V of calpain 2 may feature 
in the membrane activation of the enzyme (chapter 3). Here, this prediction was 
investigated using a variety of biophysical techniques to study the conformational 
behaviour and lipid interactive properties of a peptide, VP1, corresponding to the 
GTAMRILGGVI segment of calpain 2. 
FTIR conformational analysis of WI showed that in aqueous solution, the 
peptide was predominantly formed from 13-sheet structures, exhibiting less evidence 
of a-helical structure (Figure 4.2A). However, confirming theoretical predictions, 
these analyses showed the peptide to adopt a-helical structure in the presence of 
DMPC (20%) and DMPS (65%) (Table 4.1; Figure 4.2B and 4.2C), suggesting that 
the GTAIvIRILGGVI segment requires the ansiotropic environment of a lipid 
........--
- - interface-toadopt-a-helical-structure: 	 ------ - 
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Figure 4.2 FTIR conformational analysis of YP1 in the presence of lipid 
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Figures 4.2 shows spectra representing FTIR conformational analyses of VP1 in 
aqueous buffer (A), in the presence of DMPC (B) and in the presence of DMPS (C). 
Annotated numbers indicate band peak absorbances and for each spectrum, the 
relative percentages of VP1 a-helical secondary structure (1650 cm 1 - 1652 cm') 
were computed. In the presence of DMPC these were 20% and in the presence of 
DMPS, 65%. All FTIR analyses were performed as described in section 4.3.3. 
Table 4.1 YP1 secondary structural contributions in the presence of lipid 
lifiid %hliU %her 
- 
- 92 
DMIPS 65 32 
DMPC 20 61 
Table 4.1 shows the relative levels of a-helical structure and (s-sheet structure 
determined in VP1, a peptide homologue of the putative oblique orientated a-helix 
forming segment identified in domain V of calpain 2 (Table 2.1). The peptide was 
either: in aqueous solution or in the presence of lipid. Conformational analysis of VP1 
was performed using FTIR spectroscopy and the resulting spectra (Figure 4.1) used to 
determine relative levels of secondary structure as described in section 4.3.3. 
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VP1 adopted relatively low levels of a-helical structure (20%) (Table 4.1; 
Figure 4.213) in the presence of DMPC monolayers yet interacted strongly with these 
monolayers, inducing a final surface pressure change of 5.0 mN m1 (Figure 4.3). 
Previous studies have shown that this peptide has only a minor effect on the lipid 
phase transition temperature and fluidity of DMPC membranes (Brandenberg et al., 
2002), indicating that the primary interaction of VP1 with DMPC monolayers may be 
with the headgroup region rather than penetration of the hydrophobic acyl chain 
region. Taken in combination, these results suggest that the interactions of VP1 with 
DMPC membranes is unlikely to involve oblique orientated a-helix formation. 
Indeed, it seeths likely that these interactions may involve f3-sheet structure, which 
was the predominant secondary structural type shown by the peptide in the presence 
of DMPC membranes (61%) (Table 4.1; Figure 4.213). 
Figure 4.3 The monolayer interactions of VPI 
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Figure 4.3 shows the typical time course for interactions of VP1 (final concentration 
20 iM) with lipid monolayers at an initial surface pressure of 30 mN m 1 , taken to 
represent that of naturally occurring membranes. Figure 4.3A shows the interaction of 
VP1 with DMPS monolayers (upper curve) where it can be seen that the peptide 
reaches maximal levels of penetration (A SP = 5.5 mN m 4 ) after 600 secs. Figure 
43A also shows that when 100 mM NaC1 was introduced into the subphase of the 
VP! - DMPS monolayer system (lower curve), the maximal levels of peptide - 
monolayer interaction were reduced by approximately 50% (A SP = 2.6 mN m 1 ) 
whist the time taken to achieve these levels was 1200 secs. Figure 4.3B shois that the 
ability of VP! to penetrate DMPC monolayers (A SP = 5.0 mN m') is comparable to 
that of the peptide to penetrate DMPS monolayers but the time taken to achieve these 
--._levels_wasisincreased_to_1200-secs.MLmqnplayer experiments were conducted as 
described in section 4.3.4. 
VP! induced a final surface pressure change of 5.5 mN m in DMPS 
monolayers, indicating a capacity to interact with these monolayers that is comparable 
to that shown with DMIPC monolayers but the use of differing mechanisms would 
appear to be involved. FTIR conformational analysis showed that VP! is 
predominantly a-helical (65%, table 4.1; Figure 4.2C) in the presence of DMPS 
membranes whilst previous studies have shown that the peptide interacts strongly with 
the acyl chain region of DMPS membranes (Braridenberg et al, 2002). Moreover, it 
can be seen from figure that the kinetics of VP1 interaction with DMPS and DMPC 
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monolayers show marked differences (Figure 4.3). With DMPC monolayers, the 
presence of the peptide led to a slow progressive increase in monolayer surface 
pressure, which showed hyperbolic type kinetics and a maximum surface pressure 
change after 1200 secs (Figure 4.3). In contrast, VP1 induced a rapid, almost linear 
rise in the surface pressure of DMIPS monolayers over 200 secs, which increased to a 
maximum surface pressure change after 600 secs. VP1 possesses a sole positively 
charged arginine residue, which suggests that electrostatic interactions between this 
residue and the anionic headgroup region of DMIPS monolayers may contribute to the 
enhanced rates of interaction observed between the peptide and these monolayers. 
This suggestion was strongly supported when 100 mM NaC1 was included in the 
DMPS monolayer subphase (Figure 4.3). It can be seen from figure 4.3 that the high 
ionic strength of this salinated subphase has greatly decreased the rate, and levels, of 
VP1 - DMPS monolayer interaction with maximal monolayer surface pressure 
changes of 2.6 mN m 1 occurring after 1200 secs. Taken overall, these results clearly 
show that the membrane interactions of VP! involve a-helix formation by the peptide 
and anionic lipid. 
To investigate the ability of VP! to interact with naturally occurring 
membranes, the haemolytic potential of the peptide was studied. VP! was found to be 
strongly haemolytic with an half-maximal lytic dose of 1.45 mM (Figure 4.4) and 
when taken with both the DMPS monolayer data shown in figure 4.2 and the 
theoretical analyses of chapter 3, these results suggest a basic model for VP1 
haemolytic action. According to this model: positively charged VP1 preferentially 
targets anionic lipid headgroups at the erythrocyte membrane interface. In this 
ansiotropic environment, VP1 adopts a-helical structure and the hydrophobicity 
gradient possessed by this a-helical structure then facilitates erythrocyte membrane 
FIJ 
penetration at a shallow angle, leading to the destabilisation of membrane lipid 
packing and haemolysis. To assist this form of membrane penetration, it seems likely 
that the arginine residue of the VP1 a-helix would engage the snorkelling mechanism 
(Segrest et al., 1990). This mechanism has been shown to enhance the levels of 
membrane penetration achieved by many membrane interactive proteins and peptides 
(Strandberg and Killian, 2003) and alleviates the energetically unfavourable 
positioning of the positive charges carried by arginine and Jysine residues within the 
hydrophobic membrane core region. In the case of the VP1 a-helix, the snorkelling 
mechanism would allow the arginine residue of this a-helix to extends its long 
hydrophobic alkyl chain, permitting deeper a-helix penetration of the erythrocyte 
membrane's hydrophobic core region yet still allowing the arginine's positively 
charged moiety to interact with anionic lipid headgroups. 
Figure 4.4 The haemolytic action of YP1 
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Figure 4.4 shows the haemolytic curve of VP1 when iricubated with human 
erythrocytes. It can be seen that a threshold concentration of 0.4 mM VP1 was 
required for haemolysis to occur whilst a concentration of 2.4 mM, VP1 led to 100% 
lysis of erythrocytes (LD50 = 1.45 mlvi). The % haemolysis was determined in 
triplicate, all as described in section 4.3.5, and the mean % haemolysis plotted as a 
function of VP1 concentration with error bars representing ± SD (n=5). 
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It can be seen from figure 4.4 that VP1 exhibits a sigmoidal type relationship 
between levels of haemolysis and VP1 concentration, which requires a threshold VP1 
concentration of 0.4 mM. This relationship implies that under the experimental 
conditions used here, VPI haemolytic action involves some form of cooperative 
action between molecules of the peptide. A number of peptides, which appear to form 
oblique orientated a-helices (Harris et al., 2002), have previously been reported to 
exhibit haemolytic ability with sigmoidal kinetics and cooperative mechanisms of 
action (Harris and Phoenix, 1997). It was suggested by Harris and Phoenix, (1997) 
that these latter peptides may utilise a "carpet" type mechanism (Dennison et aL, 
2004) in their haemolytic action; a mechanism, which could also explain the 
sigmoidal kinetics of VP1 haemolysis. Using this mechanism, erythrocyte membrane 
destabilisation by VP1 would lead to membrane lesions whose levels increase with 
rising peptide concentration. At VP1 concentrations below 0.4 mM, the accumulating 
effects of these lesions would not be sufficient to lead to significant erythrocyte cell 
Jysis. However, as VP1 concentratiori increases above this threshold peptide level, 
progressively greater cooperative interaction between the formation of VP1-mediated 
membrane lesions would lead to increasingly higher levels of erythrocyte cell lysis 
until at 2.5 mM peptide (Figure 4.4), total haemolysis would occur. It is interesting to 
note that the peptides studied by Phoenix and Harris (1997) contrast with VP1 in that 
the former peptides were haemolytic at micromolar concentrations and showed no 
requirement for anionic lipid in their membrane interactions (Han -is et al., 1997). It is 
well established that erythrocyte membranes possess an asymmetric distribution of 
anionic lipids with the extracytoplasmic leaflet depleted in such lipids (Op den Kamp, 
1979) and it may therefore be that the relatively high levels of VP1 required for 
haemolysis reflect the relative inaccessibility of anionic lipid to the peptide. 
In conclusion, these studies have shown that VP1, a peptide homologous to the 
GTAMIRILGGVI segment of domain V in calpain 2, was able to form lipid interactive 
a-helical structure. Anionic lipid was shown to enhance the levels of a-helicity 
adopted by VP1 and appeared to facilitate membrane penetration by the peptide via 
mechanisms that were consistent with its adoption of oblique orientated a-helical 
structure. It is also speculated that VP1 may achieve deeper levels of membrane 
penetration by use of the snorkelling mechanism (Phoenix et al., 2002; Segrest et al., 
1992). It has previously been shown that calpain 2 activity is modulated by the 
presence of anionic lipid (Arthur and Crawford, 1996) and in combination, these 
results clearly support the role predicted for domain V of calpain 2 in the membrane 
activation model of the enzyme (chapter 2). 
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Chapter 5 
Investigation into the role of the calpain 2 small 
subunit in the lipid / membrane activation of the 
enzyme. 
M. 
5.1 ABSTRACT 
Calpain 2 is a heterodimeric enzyme whose in vivo requirement forCa 2 
appears to be lowered by lipid / membrane interactions. Colorimetric assay showed 
calpain 2 to require 4 mM Ca 2 for 100% proteolytic activity, as defined by this assay, 
but to show negligible activity in the presence of 1 mlvi Ca 2t In contrast, calpain 2 
showed significant proteolytic activity at this 1 mlvi Ca 2 level, in the presence of 
either: DMPI, DMPS, DMPC or DMPE, with this activity ranging between 37% and 
77% of the protein's full enzymatic activity. The large subunit of calpain 2 (LS-
calpain 2) is proteolytically active in the absence of the calpain 2 small subunit and 
when assayed under conditions corresponding to those used for calpain 2, LS-calpain 
2 was found to require the presence of 6 mlvi Ca 2 for 100% proteolytic activity. 
However, in the presence of either: DMPI, DMPS, DMPC or DMPE, LS-calpain 2 
showed no evidence of reduced Ca 2 requirements for proteolytic activity and based 
on these combined results, it is suggested that the lipid activation of calpain 2 requires 
the presence of this enzyme's small subunit. In addition, when compared to 
- - - - zwitterionic lipid under corresponding conditions, anionic lipid induced an 
approximate twofold enhancement of calpain 2 activity (70% - 77% as compared to 
37% - 49%) and a similar enhancement in average rates of anionic lipid monolayer 
interaction (changes in surface pressure (ASP) = 1.5 x 10 3 mN M' sec 1 at 10 mN M' 
as compared to ASP = 5.0 x 104 mN M' sec' at 10 mN M1). It is suggested that an 
electrostatically driven affinity for anionic lipid may help lower the Ca 2 requirement 
for calpain 2 activation. 
5.2 INTRODUCTION 
Calpain 2 is a heterodimeric enzyme with the large subunit housing the 
enzyme's active site and it is generally believed that in vivo lipid / membranes lower 
the enzyme's Ca 2 
 requirement for activation (section 1.5.3.1; Biswas et al., 2004). It 
was found nearly a decade ago that the large subunit of calpain 2 (LS-calpain 2) 
possesses full catalytic activity in the absence of the enzyme's small subunit 
(Yoshizawa et al., 1995). More recent studies have identified a Ca 2tregulated lipid 
binding site in domain 1171 of the calpain 2 large subunit (Tompa et al., 2001) and it 
was suggested that this site may mediate the role of lipid binding in calpain 2 
activation (Hood et al., 2003; (Joll et al., 2003). These results clearly suggest that the 
small subunit of calpain 2 may not be required for the enzyme's activation. However, 
sequence analysis (chapters 2) and biophysical studies (chapter 3; Crawford et al., 
1996) have suggested that segments in domain V, and thereby the small subunit, of 
calpain 2 may participate in the lipid / membrane activation of the enzyme. 
Supportive of this suggestion, recent studies on mice have shown that the 
homozygous disruption of CAPN4, the allele for this subunit, results in embryonic 
lethality, clearly suggesting that the small subunit of calpain 2 is both an essential and 
integral part of the enzyme's function (Arthur et al., 2000; Zimmerman et al., 2000). 
Reinforcing these observations, more recent studies have shown that a novel tissue 
specific form of the subunit is expressed in humans, suggesting biological 
diversification by this small subunit and thereby, implying functional relevance 
(Schad et al., 2002). 
Here, it is attempted to ascertain whether the small subunit of calpain 2 is 
essential or dispensable for the enzyme's activation. Colorimetric assay is used to 
determine the Ca2 requirement for both calpain 2 and LS-calpain 2 to proteolyse 
casein and then the ability of a range of lipids to lower these Ca 2 requirements is 
investigated. The results show lipid is able to lower the Ca 2 requirements for calpain 
2 activation but not that of LS-calpain 2. Based on these results, it is suggested that 
the presence of the calpain 2 small subunit is required to facilitate the lipid activation 
of the enzyme. It is also shown that anionic lipid has an enhanced ability to lower the 
Ca2 requirements of calpain 2 activation when compared to zwitterionic lipid. Based 
on lipid monolayer studies, it is suggested that this ability could be related to an 
electrostatically driven preference for anionic lipid by the enzyme. 
5.3 MATERIALS AND METHODS 
5.3.1 Reagents 
Dimyristoyl phosphatidylserine, climyristoyl phosphatidylcholine, all solvents, 
which were of spectroscopic grade, N, N-dimethylated casein and LS-calpain 2 (the 
enzymatically active 80 kDa subunit, derived from rabbit skeletal muscle) were 
purchased from Sigma (UK). A recombinant form of calpain 2, derived from the rat 
enzyme, was purchased from Calbiochem (UK). Both calpains were stored in enzyme 
buffer [20 mM imidazole, pH 7.5; 1 mM EGTA; 1 mM EDTA; 5 mM 2-mercapto 
ethanol] at 4°C. 
5.3.2 The preparation of phospholipid small unilamellar vesicles 
Small unilamellar vesicles (SIJV's) were prepared according to the method of 
Keller et cii., (1992). Essentially, phospholipid / chloroform mixtures were dried with 
nitrogen gas and hydrated with enzyme buffer to give a final phospholipid 
concentration of 2.0 mM. The resulting cloudy suspensions were sonicated at 4°C 
with a Soniprep 150 sonicator (amplitude 10 microns) until clear suspensions resulted, 
which were then centrifuged (15 mm, 3000 g, 4 °C). The resulting cleared suspensions 
were taken as stock solutions for immediate use. 
5.3.3 Enzyme assay conditions 
Enzymatic activity was assayed using a modified form of the colorimetric 
assay developed by Kawashima et cii., (1984): Either LS-calpain 2 or calpain 2, in 250 
Al of enzyme buffer [20 mM imidazole, pH 7.5; 1 mM EGTA; 1 mM EDTA; 5 mM 
2-mercapto ethanol], was added to: 250 Al of enzyme buffer: 100 Al of 50 mM 
cysteine solution; 100 Al of 4% (w/v) N, N-dimethylated casein in buffer [0.5 M 
imidazole, pH 7.5]; 200 Al of deionised water and 100 Al of CaCl2 that varied 
between 10 mM, 20 mM, 30 mM, 40 mM, 50 mM or 60 mM. Each of these mixtures 
was then incubated for 1 hour at 30°C, the reaction stopped by the addition of 1.0 ml 
5% (w/v) of Trichloracetic acid, the whole centrifuged at low speed (1500 g, 15 mm, 
30°C). After centrifugation, 400 Al of the supernatant was added to: 100 Al of 0.7 M 
Na2CO3 in 0.1 M NaOH; 100 Al of 2 M iodoacetic acid in 2M NaOH and 2.0 ml of: 
0.5% (w/v) CuSO 4, 1.0% (w/v) K Na tartrate and 1.5% (w/v) Na2CO3 in 0.1 M 
NaOH; in the ratio 1:1:50 (v/v). The mixture was left for 10 mm, 200 Al of IM Folin-
Phenol reagent added, the whole left for 1 hour and the absorbance at 750 nm 
measured, all at 30°C. These absorbance values were used as relative measures of 
enzymatic activity. 
5.3.4 Units of enzymatic activity 
Using the above protocol (section 5.3.3), levels of either LS-calpain 2 or 
calpain 2 were arbitrarily chosen and used to determine the respective minimum 
levels of Ca2 that permitted the enzymatic activity of these proteases. The above 
protocol (section 5.3.3) was then used to determine the quantity of either LS-calpain 2 
or calpain 2 that produced an absorbance change of 1.0 when assayed with casein as 
substrate for one hour in the presence of the minimum level of Ca 2 required for 
enzymatic activity. In each case, this quantity of enzyme was defined as possessing 
one unit of enzymatic activity and an absorbance change of 1.0 taken to represent 
100% enzyme activity as described by Kawashima. 
5.3.5 The lipid activation of LS-calpain 2 and calpain 2 
As control experiments, levels of either LS-calpain 2 or calpain 2, which 
possessed one unit of enzyme activity (section 5.3.4), were assayed as described in 
section 5.3.3. Similar experiments were performed except that the addition of 250 jil 
of enzyme buffer was replaced by the addition of 250 gl of enzyme buffer containing 
SIN's of either DMPS or DMPC, prepared as described in section 5.3.2. In all cases, 
experiments were conducted in triplicate and the mean absorbance determined. This 
mean absorbance was used to express enzyme activity as a percentage relative to the 
standard that an absorbance of 1.0 represented an enzymatic activity of 100%. (section 
me 
5.3.4). The relative % enzymatic activity was then plotted as a function of the final 
Ca2 
 concentration used under the assay conditions of section 5.3.3 with error bars 
representing ± SD (Figures 5.1 and 5.2). 
5.3.6 Monolayer interations of calpain 2 
All monolayer equipment was supplied by NIMA (UK). Surface tension was 
monitored by the Wilhelmy plate method using a microba]ance (Demel,1974, Figure 
4.1). Studies were conducted using a 5 x 15 cm Teflon trough containing 80 ml of 
either 10 mM Tris (pH 7.5) or this buffer supplemented with NaCl (final 
concentration 100 mM). The trough was equipped with moveable barriers, which 
responded to the microbalance and could be adjusted to maintain monolayers at 
constant surface area. Monolayers were formed by spreading pure phospholipids (10 
mM) in chloroform onto the subphase, followed by compression to give the desired 
final surface pressure. 20 j.tmol. Stock calpain 2 was introduced to the subphase via a 
reservoir extending below the monolayer and the subphase was continuously stirred 
by a magnetic bar. Ca1ain 2 - lipid monolayer interactions were monitored via 
changes in monolayer surface pressure and recorded as a function of time (figure 5.3). 
5.4 RESULTS AND DISCUSSION 
It has previously been reported that lipid is able to lower the Ca 2 
requirements of calpain 2 for activation but no corresponding studies on LS-calpain 2 
seem to have been conducted. Clearly, a comparison of such studies may provide 
information on the participation / non-participation of calpain subunits in the lipid 
activation of calpain 2 and such a comparison is undertaken here. 
Colorimetric assay of LS-calpain 2 (section 5.3.5) showed that the enzyme 
required Ca2 
 levels of 6 mM for 100% activity (figure 5.1), which was defined as an 
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absorbance change of 1.0 after an incubation of one hour with casein as substrate 
(section 5.3.4). However, LS-calpain 2 exhibited no significant activity at Ca 2 
concentrations !~ 5 mM (Figure 5.1). These experiments were repeated in the presence 
of either: DMPI, DMPS, DMIPC or DMPE. No significant LS-calpain activity was 
detected at Ca 2 concentrations :5 5 mM, showing that these lipids had no significant 
ability to reduce the Ca 2 levels required for activation of the enzyme (Figure 5.1). It 
has been suggested that domain ifi of calpain 2 may play a role in the lipid-mediated 
reduction of the Ca2t  levels required for activation of the enzyme (Hood etal., 2003; 
Goll et al., 2003). Clearly, LS-calpain 2 also possesses domain ifi but the results 
shown in Figure 5.1 show that under our experimental conditions, the ability of this 
domain to interact with lipid does not lead to reductions in the Ca 2 requirements of 
LS-calpain 2 for activity. These results clearly suggest that additional factors are 
involved in the lipid-mediated reduction of Ca 2 requirements for calpain 2 activation. 
Figure 5.1 The lipid activation of LS-calpain 2 
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Figure 5.1 shows LS-calpain 2 activity as a function of Ca  21  concentration when assayed with 
casein as substrate, all as described in section 5.3.3. The enzyme required Ca 2 levels of 6 
mM for 100% activity and exhibited no significant activity at Ca 2 concentrations !~ 5 mM. 
Corresponding assays were performed in the presence of either: DMPI, DMPS DMPC or 
DMPE and it was found that these lipids had no significant ability to reduce the levels of Ca 2 
required for LS-calpain 2 activity, therefore producing data points coincident with those of 
the corresponding assay of LS-calpain 2 assay in the absence of lipid. LS-calpain 2 activity 
was expressed as the mean relative % activity of triplicate determinations and Ca 2 levels as 
the final Ca2 concentration used under assay conditions, all as described in section 5.3.5, 
with error bars representing ± SD. (n=5) 
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Colorimetric assay of calpain 2 (section 5.3.5) showed that the enzyme 
required the presence of 4 mM Ca 2 to exhibit 100% activity with casein as substrate 
(Figures 5.2A 
- 5.2D). As Ca2 levels were decreased, the proteolytic activity of 
calpain 2 ra1iidly decreased and at Ca 2 concentrations :~ 2 mM, the activity of the 
enzyme was < 10% (Figures 5.2A - 5.2D). At 1 mM Ca 2 , the enzymc showed 
negligible proteolytic activity (6%) but the activity of the enzyme was increased to 
77% in the presence of DM91, 70% in the presence of DMPS, 49% in the presence of 
DMYC and 37% in the presence of DMPE (Figures 5.2A 
- 5.2D). As shown in figure 
5.2, these lipid-mediated effects decreased with increasing Ca 2 until at 4 mM Ca2 , 
no significant effect of lipid on the activity of calpain 2 was observed. These 
experiments clearly show that lipid is able to mediate reductions in the Ca 2 
requirements of calpain 2 for activity. Moreover, when these results are taken with 
those described above for corresponding experiments on LS-calpain 2 (Figure 5.1), 
they strongly suggest that the presence of the calpain 2 small subunit is required for 
the lipid-mediated activation of this latter enzyme. 
Comparison of Figures 5.2A and 5.213 to Figures 5.2C and 5.2D show that the 
proteolytic activity of calpain 2 is upto approximately twofold enhanced in the 
presence of DMPI and DMPS when compared to that in the presence of DMIPC and 
DMPE (70% 
- 77% as compared to 37% - 49%). These results clearly suggest that 
calpain 2 may have a preference for association with anionic lipid and to study this 
suggestion, the interactions of the enzyme with lipid monolayers were observed. 
Calpain 2 showed high levels of interaction with both DMPS and DMYC monolayers 
at an initial surface pressure of 10.0 mN M 1 (Figure 5.3). Moreover, the final surface 
pressure changes induced by calpain 2 in both cases were comparable at 6 mN M' 
and 5 mN M' respectively (Figure 5.3), suggesting that monolayer insertion by 
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Figure 5.2 The lipid activation of calpain 2 
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Figure 5.2 shows calpain 2 activity plotted as a function of Ca 2 concentration when assayed 
with casein as substrate, all as described in section 5.3.3, either in the presence () or 
absence (•) of. DMPJ (Figure 5.2A), DMPS (Figure 5.2131), DMPC (Figure 5.2C), DMPE 
(Figure 5.21)). It can be clearly seen from these figures that in the absence of lipid, calpain 2 
shows negligible activity at Ca 2 concentrations :~ 2 mM. However, the enzyme shows 
significant proteolysis at Ca 2 concentrations 5 2 mM when in the presence of each lipid 
I]! 
C.  
D. 
m a 
C. 
C 
0 
studied, which at 1 mM Ca 2 ranged between 37% -77%. It can also be seen that, at these 
Ca 21 
 concentrations, the proteoltyic activity of calpain 2 was generally greater in the presence 
of anionic lipid (70% -77%, Figures 5.2A and 5.28) when compared to zwitterionic lipid 
(37% - 49%, Figures 5.2C and 5.21)). Calpain 2 activity = the mean relative % activity ± SD. 
(n=5) 
the enzyme was hydrophobicity driven. However, the kinetics of these monolayer 
interactions showed fundamental differences. The interaction of calpain 2 with DMPC 
monolayers were relatively slow with final surface pressure changes reached after 
approximately 10,000 sec (Figure 5.313), giving an average rate of surface pressure 
change of 5.0 x 10 mN M' sec* In contrast, the rates of interaction of calpain 2 
with DMJDS 
 monolayers were much higher with final surface pressure changes 
reached after a period of 4000 sec (Figure 5.3A), giving an average rate of surface 
pressure change of 1.5 x iO 3 mNM' sec* 
In combination, these results suggest that electrostatic interactions between 
cationic regions of calpain 2 and DMPS headgroups accelerate the rates of interaction 
between the enzyme and this lipid when compared to those observed between calpain 
2 and DMPC monolayers. Strongly supporting this suggestion, it was also found that 
when 100 mM NaCl was included in the subphase of DEWS monolayers, the high 
ionic strength of the salt reduced the rates, and levels, of surface pressure change 
shown between calpain 2 and these monolayers by approximately 40% (lower curve, 
Figure 5.3A). Hence the overall results clearly suggest that, whilst calpain 2 has a 
genera] hydrophobicity-driven ability to interact with lipid, the enzyme has an 
electrostatically-driven preference for interaction with anionic lipid. Such a preference 
for anionic lipid could explain the enhanced ability of such lipid to reduce the levels 
of Ca2 required for calpain 2 activation observed in Figure 5.2. Moreover, it was 
suggested above that the calpain 2 small subuhit, and thereby the GTAMRILGGVI 
segment of domain V, may be required for the lipid / membrane activation of the 
I!ZI 
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enzyme. It would seem significant that this segment was also shown to exhibit a 
preference for anionic lipid in chapter 4, further supporting the view that this segment 
may participate in the lipid-mediated activation of calpain 2. 
Figure 5.3 The monolayer interactions of calpain 2 
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Figure 53A and 5.38 show the interactions of calpain 2 with monolayers at an initial surface pressure 
of 10.0 mN MS', all as described in section 5.3.6. The enzyme showed comparable final surface 
pressure changes with DMPS monolayers (upper curve, Figure 5.3A) and DMPC monolayers (Figure 
538), suggesting a major role for hydrophobic forces in these interactions. However, when compared 
to DMPC monolayers (Figure 5.38) the accelerated rates of changes in surface pressure shown by 
calpain 2 with DMPS monolayers (upper curve, Figure 53A), suggests an electrostatically driven 
preference for anionic lipid. Supporting this suggestion, 100 mM NaCl reduced the levels, and rates, of 
surface pressure changes associated with calpain 2 DMJ'S interactions (lower curve, Figure 5.3A) by 
circa 40%. In contrast to these previous results. Figures 5.3C and 5.31) show DMPS and DMPC 
monolayers respectively, at an initial surface pressure of 30.0 mN M', mimetic of naturally occurring 
membranes. Calpain 2 was introduced into the subphase of these monolayers but showed no ability to 
introduce changes in their surface pressures. In combination, these results suggest that lipid-packing 
density may be important to the lipid interactions of calpain 2. 
In summary, these results strongly support a role for the calpain 2 small subunit in the 
lipid / membrane mediated activation of the enzyme. However, it is interesting to note 
that in the present study, this enzyme showed no evidence of interaction with 
monolayers of either DMIPS or DMPC at surface pressure of 30 mN MS', which is 
representative of naturally occurring membranes (Figure 5.3C). Whilst these results 
do not preclude the enzyme from membrane interaction, they suggest that lipid-
packing density is important to the lipid interactions of the enzyme. Indeed, it is 
noticeable that many of the studies advocating calpains to be membrane interactive 
have been performed using lipid vesicles. Due to their high curvature, these bodies 
possess lower lipid packing densities in their surface regions and it may be that such 
bodies feature in the lipid activation or biological activity of calpain 2. 
Consistent with this suggestion, Yudin a' al., (2000) recently showed that 
--calpain. 2, ancLcalpain 1, were_strongIyasLspciated_with  theacrosomal reaction of 
cyanomolgus macaque sperm. These enzymes were localised to a region between the 
acrosomal vesicle membrane and the plasma membrane prior to this reaction and 
strongly associated with the acrosomal shroud after. It appears that calpain 
participation in this reaction involves the promotion of fusion between the acrosomal 
membrane with the sperm plasma membrane. Interestingly, the promotion of 
membrane fusion is an activity strongly associated with oblique orientated a-helical 
structure; protein architecture, which chapter 3 predicted was likely to be formed by 
the GTAMRILGGVI segment. 
CHAPTER 6 
Final discussion and future work 
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6.1 CONCLUDING DICUSSION AND FUTURE WORK 
The precise physiological role(s) of calpains in the lens are not fully 
understood but it has been postulated that following differentiation, calpains remain in 
mature fibre cells to degrade damaged lens proteins that accumulate during the life of 
the lens. On this basis, two hypotheses to explain the role of calpains in cataract have 
been proposed. In the first, loss of lens calpain activity leads to pathologically 
elevated levels of damaged proteins, reduced lens optical performance and cataract 
(David and Shearer, 1989). However, it clearly emerges from our review of the 
literature in chapter 1 that the unregulated calpain-mediated proteolysis of crystallins 
males a contribution to cataract in aged lenses and calpain inhibitors have been 
shown to be able to retard these processes. These observations are clearly inconsistent 
with the above hypothesis and rather, support the alternative hypothesis that the 
pathologically-mediated over-activation of calpains cause the accumulation of 
partially-degraded lens proteins, thereby contributing to age-related and other forms 
of cataract (David and Shearer, 1989). This latter hypothesis is also consistent with 
our studies on porcine lenses IiiEIi ihMi the ãThdlö ëVãtiöifOf Ca 2 'ln 
these lenses produced an almost linear response in levels of cataract, which, 
moreover, could be reduced by calpaininhibitors (chapter 2). These latter studies also 
suggested that the over-activation of calpain 2 may onthbute to porcine cataract, 
which has previously been shown to contribute to cataract in other animals and 
appears to be the major contributor to human cataract (chapter 1). 
It has been proposed that lipid I membranes may mediate the activation of 
calpain 2 by lowering the enzyme's Ca 2 requirements for proteolysis, although there 
is some debate as to whether the enzyme's small subunit participates in this process 
M. 
(chapter 1). The present study has shown dimeric calpain 2 to be membrane 
interactive and that lipid is able to reduce the Ca 2 requirements of this form of the 
enzyme for activation but shows no corresponding ability with monomeric calpain 2. 
This latter form of calpain 2 is a fully active protease comprising the intact large 
subunit of calpain 2 but lacking the small subunit of the enzyme and clearly, these 
combined results strongly support a role for this subunit in the lipid / membrane 
activation of calpain 2 (chapter 5). Consistent with this suggestion, the combined 
results of chapter 4 and 5 have suggested that a segment, GTAMRILGGVT, in domain 
V of the calpain small subunit may play a role in the in the lipid / membrane 
activation of the enzyme. Based on the combined data of these two chapters, a model 
for the membrane interaction of this domain V segment is presented: in figure 6.1. 
Incorporating the model of Figure 6.1, and the data of chapter 5, the following 
sequence of event is suggested to occur in the lipid activation of dimeric calpain 2: 
The cytostolic enzyme is first translocated (chapter 1) to the membrane / lipid bodies 
(chapter 5). In the presence of anionic lipid, activation of the enzyme proceeds 
(chapter 5) and the segment, GTAMIRILGGVI, in domain V of the calpain 2 small 
subunit forms an oblique orientated a-helix (chapter 3 and chapter4) The 
hydrophobicity gradient possessed by this a-helix acts in conjunction with snorkelling 
interactions between its arginine residue and anionic lipid to achieve angled insertion 
into the membrane / lipid surface and penetration to the level of the hydrophobic acyl 
chain region (Figure 6.1). These interactions lead to further conformational changes in 
the calpain 2 small subunit that result in the activation of the enzyme at lower Ca 2 ' 
levels. 
It is envisaged that future work will have two major foci. Membrane 
penetration by the GTAMRILGGVI segment will be further investigated using 
Figure 6.1 The lipid / membrane interaction of the GTAMRILGGVI segment 
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Figure 6.1 shows a schematic representation of the lipid surface / membrane 
interaction of the calpain 2 segment, GTAMRILGGVI, in which the segment is 
represented as a ribbon structure. Due to its hydrophobicity gradient, the segment is 
depicted as penetrating the lipid surface I membrane in an oblique orientation with its 
strongly hydrophobic C-terminal region in the hydrophobic lipid acyl chain region. 
The angle of membrane penetration was arbitrarily chosen as 45° but most tilted 
peptides adopt orientations between 300  and 60° (Brasseur et al., 2000). Also 
represented is snorkelling by the segment's arginine residue with the positively 
charged sidechain of the residue extending up to interact with negatively charged 
moieties in the lipid headgroup region. Figure 6.1 is not to scale bUt geometrical 
interpretation of previously presented data (Stopar et al., 2003) shows that the angled 
arrangement of the OTAIvIRILGOVI a-helix in relation to the membrane surface 
could allow snorkelling by the segment's arginine sidechain. 
neutron lamellar diffraction and a series of deuterated peptide homologues of the 
segment. These studies can indicate the relative bilayer locations of the deuterated 
residues and simple geometry will allow an estimate of the angle of penetration used 
by the segment. The other major focus of future studies will be on the membrane 
interactions of the lone dimeric calpain 2 small subunit. Clones of genes for both this 
intact subunit and, this subunit lacking most of the GTAMRILGGVI segment, are 
now available. FT'IR spectroscopic analysis and monolayer studies on the membrane 
interactions of the proteins expressed by these genes will provide information on the 
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role(s) played by the GTAMIRILGGVI segment in the lipid interactions of the calpain 
2 small subunit, and thereby, possibly the enzyme's lipid / membrane activation 
mechanism. 
As a final comment, the mainstay of the present treatment of cataract is 
surgery: Cataract surgery was described as long ago as 300 BC in the treatise of 
'Susruta', from the ancient Indian civilisation (Biswas et al., 2001). A revolution in 
the field of cataract surgery was initiated by Harold Ridley, who in 1948 designed the 
intra-ocular lens implant, and Charles Kelman, who in 1967 developed phaco- 
emulsification surgery, the ophthalmic version of keyhole surgery (Olsen et al., 2003). 
Modem cataract surgery, although very successful in dramatically reversing the visual 
debility induced by cataract (Rubin et cxl., 1993) is a highly skilled surgery with 
expensive and sophisticated instrumentation requiring considerable investment in 
manpower and technology. Even with an excellent success rate, there is a 1:300 
incidence of severe complications resulting in permanent blindness (Masket, 1992; 
Powe et aL, 1994). As with many other medical conditions where surgical treatment 
has been replaced over time by drug-based medical therapy, which is easily 
p1-event ataract i —sp—erhaps  
of cataract treatment. Significant advances are continuously being made in the 
development of membrane permeable calpain inhibitors, which are suitable for topical 
aministration in the eye. Research into the molecular genetics of cataract is also 
underway and advances have been made in understanding the genetic basis of 
congenital cataract. This may lead to the introduction of novel medical therapies, 
possibly involving gene manipulation, to prevent or treat cataract (Francis et aL, 
1999). Continued progress in this direction could lead to the non-surgical treatment of 
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cataract - which would perhaps be the next revolution and the Holy Grail of cataract 
treatment 
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